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CHAPTER 1 
INTRODUCTION 
1. Inflammation 
Inflammation is a protective response intended to abolish the initial cause of cell injury as well as 
the necrotic cells and tissues from the original insult[1]. Pathogens,abrasions,chemical irritations, 
distortion or disturbances of cells and extreme temperatures causes inflammation. It is an attempt 
to dispose of microbes,toxins or foreign materials, at the site of injury, to prevent their spread to 
other tissues, and to prepare the site for tissue repair in an attempt to restore tissue homeostasis 
.  
1.2Signs of inflammation 
The four cardinal signs and symptoms of inflammation,described by Roman writer Celsus 1st 
century A.D are as follows[2][3] 
 rubor (redness); 
 tumor (swelling); 
 calor (heat); and 
 dolor (pain). 
Inflammation can also cause a loss of function in the injured area depending on the site and 
extent of the injury and thus a fifth sign functio laesa (loss of function)  was also added by 
Virchow[4] 
 
1.3Types of inflammation 
            According to the defence capacity of the host and duration of response , inflammation is 
classified as; 
 Acute inflammation 
 Chronic inflammation 
1.3.1 Acute inflammation  
Acute inflammation which has  a short duration lasting from few minutes to a few days which is 
characterised by fluid and plasma protein exudation and neutrophilic leukocyte accumulation[5]. 
Acute inflammation has two major components 
Vascular changes:- 
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Changes in vessel calibre resulting in increased blood flow (vasodilation) and structural changes 
that permits plasma proteins to leave the circulation (increased vascular permeability) 
Cellular events:- 
Movement of leukocytes from the microcirculation and accumulation in the focus of the 
injury(cellular recruitment and activation) 
 
1.3.1.1 Vascular changes in acute inflammation 
 Changes in vascular calibre and flow 
Changes in blood vessels begin rapidly after infection or injury but may develop at variable 
rates,depending on the nature and severity of the inflammatory stimulus. 
 After transient vasoconstriction, arteriolar vasodilation occurs,which increase the blood 
flow locally and engorgement of the downstream capillary beds. This vascular expansion 
is the cause of the erythema and warmth characteristically seen in acute inflammation. 
 As the microvasculature becomes more permeable,protein rich fluid moves into the 
extravascular tissues.This causes the red blood cells to become more concentrated 
thereby increasing blood viscosity and slowing the circulation,known as stasis 
 As stasis develops, leucocyteswill start to accumulate along the vascular endothelial 
surface, a process called margination.. 
 Increased vascular Permeability. 
In the early phase of inflammation, arteriolar vasodilation and increased volume of blood flow  
lead to a rise in intravascular hydrostatic pressure ,resulting in movement  of fluid from 
capillaries into thetissues. This fluid, called as transudate is essentially an ultra filtrate of blood 
plasma and contains little protein. However, transudation is soon eclipsed by increasing vascular 
permeability that allows the movement of protein rich fluid and even cells(called an exudate) 
into the interstitium. The loss of protein rich fluid into the perivascularspace reduces the 
intravascular osmotic pressure and increases the osmotic pressure of the interstitial fluid. The net 
result is the outflow of water and ions into the extravascular tissues. Fluid accumulation in 
extravascular spaces is called edema, The fluid may be a transudate or exudates. Whereas 
exudates are typical of inflammation, transudates accumulate in various non inflammatory 
conditions. 
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1.3.1.1.1Mechanisms contributing vascular permeability 
a.Endothelial cell contraction leading to intercellular gaps in postcapillary venules 
-An immediate transient process which is a reversible process elicited by 
histamine,bradykinin,leukotrienes and many other chemical mediators when bound to the 
specific receptors due to endothelial contraction. 
b.Endothelial injury results in vascular leakage by causing endothelial cell necrosis and 
detachment. 
-Direct injury to endothelial cells causes vascular leakage which begins immediately after the 
injury and persist for several hours until the damaged vessels are thrombosed or repaired. 
c.Leukocyte-mediated endothelial injury. 
-Occur as a consequence of accululation of leukocyte along the vessel wall and the activated 
leukocytes release many toxic mediators that cause endothelial injury or detachment 
d.Increased transcytosis of proteins via  an intracellular vesicular pathway. 
-Augments venular permeability especially after exposure to certain mediators such as vascular 
endothelial growth factor.(VEGF). 
e.Leakage from new blood vessels. 
-Tissue repair involves angiogenesis and these vessel sprout remain leaky until proliferating 
endothelial cells mature sufficiently to form intracellular junctions. 
 
1.3.1.1.2 Chemistry of vasodilation in acute inflammatory response 
The haemodynamics in capillaries and venules are controlled by the precapillary arteriole and the 
post capillary venule. The vascular tone is dependant upon the smooth muscle coat in the media 
and is under the contol of the control of a number of neuroendocrine influences.some of these 
vasoregulatory agents include 
 Vasoconstrictors:-Leukotrienes, Endothelin, Thromboxane, sympathetic stimuli, 
catecholamines 
 Vasodilators:- PGI2,PGD2, PGE2, Nitric oxide, Histamine, Parasympathetic stimuli, 
Serotonin 
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1.3.1.1.3 Microvascular thrombosis 
The contact between the plasma and the collagen of the basement membrane as well as the 
platelets and the basement membrane activates the clotting cascade. The result is platelet 
aggregation, fibrin deposition causing a small thrombus to form in the capillary. The result of 
such thrombi is to further obstruct the blood flow thus causing more capillary distension, more 
accumulation of leukocytes and red cells and greater movement of these elements out of the 
capillary. Another major role of the fibrin precipitation is that the fibrin threads provide a 
scaffolding for the leukocytes to move like “climbers on the rope”. 
 
1.3.1.1.4 Relative tissue hypoxia and lymph nodes 
The stagnation of blood quickly drains out the oxygen from the red cells and allow accumulation 
of carbon dioxide and with delay in the arrival of more cells,there develops a state of local 
hypoxia and anoxia.The change in the milieu promotes increased capillary permeability. 
 
1.3.1.1.5 Involvement of lymphatics and lymph nodes   
Normally the passage of fluids into the tissue spaces causes greater drainage of fluid into the 
lymphatics to restore the balance. Since the inflammatory fluid is plasma, and contains blood 
cells it is an exudates. Not only do the capillaries find it difficult to absorb the larger molecules 
but the clotting of the fluids in the tissue further obstructs the lymphatic flow. But in most acute 
inflammations, the lymphatics also get dilated and may become red as they transport the cells 
and fluids to the regional lymph node. This presents sometimes with very painful thin streaks of 
inflamed lymphatics. 
 
1.3.1.2 Cellular events : leukocyte recruitment and activation. 
An important function of the inflammatory response is to deliver leukocytes to the site of injury 
and to activate them. Leukocytes ingest offending agents,kill bacteria and other microbes and 
eliminate necrotic tissue and foreign substances. A price that is paid for the defensive potency of 
leukocytes is that, once activated, they may induce tissue damage and prolong inflammation, 
since the leukocyte products that destroy microbes can also injure host tissues. Therefore key to 
normal function of leukocytes in host defence is to ensure that they are recruited and activated 
only when needed. 
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1.3.1.2.1 Leukocyte recruitment 
The sequence of events in the recruitment of leukocytes from the vascular lumen to the 
extravascular space consist of 
a. Margination, adhesion to endothelium and rolling along the vessel wall. 
b. Firm adhesion to the endothelium 
c. Transmigration between endothelial cells; and 
d. Migration in interstitial tissues towards a chemotactic stimulus. 
 Margination and rolling 
As blood flows from capillary venules, circulating cells are swept by laminar flow against the 
vessel wall. In addition,the larger white cells tends to move slower than the smaller red cells. As 
a result, leukocytes are pushed out of the central axial column and thus have a better opportunity 
to interact with lining endothelial cells, especially as stasis sets in. This process of leukocyte 
accumulation at the periphery of the vessels is called margination. Subsequently leukocytes 
tumble on the endothelial surface, transiently sticking along the way, a process called rolling. 
The weak and transient adhesions which are involved in rolling are mediated by the selectin 
family of adhesion molecules. Selectins are receptors expressed on leukocytes and endothelium 
which contain an extracellular domain that binds sugars. Selectins binds sialyted 
oligosaccharides,that are attached to mucin like glycoproteins on various cells. The three 
members of this family are 
 E- selectin(CD62E) , expressed on endothelial cells; 
 P-selectins(CD62P), present on endothelium and platelets. 
 L-selectins(CD62L), present on the surface of leukocytes. 
 Adhesion and transmigration. 
The adhesion is mediated by integrins expressed on leukocyte cell surfaces interacting with their 
ligands on endothelial cells. Integrins are transmembrane heterodimeric glycoproteins (composed 
of different α andβ chains) that also functions as cell receptors for extracellular 
matrix.Chemokines are chemoattractant cytokines that are secreted by many cells at site of 
inflammation and are displayed bound to proteoglycans on the endothelial surface.When the 
adherent leukocytes encounter the displayed chemokines, the cells are activated, and their 
integrins undergoes conformational changes and cluster together, thus converting to a high 
affinity form. At the same time, other cytokines notably TNF and IL-1, activate endothelial cells 
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to increase their expression of ligands for integrins. The result of cytokine stimulated 
increasedintegrin affinity and increased expression of integrin ligands is the stable attachment of 
leukocytes to endothelial cells at sites of inflammation. 
After getting detained on the endothelial surface, leukocytes drift through the vessel  wall 
primarily by squeezing between cells at intercellular junctions. This movement of leukocytes 
called diapedesis, which occurs mainly in the venules of the systemic vasculature. movement of 
leukocytes is driven by chemokines produced in extravascular tissues, which stimulate 
movement of the leukocytes in the direction of their chemical gradient. After  passing through 
endothelium, leukocytes cross vascular membranes by focally degrading them with secreted 
collagenases. 
 Chemotaxis 
The chemotactic factor-mediated transmigration of leucocytes after passing several barriers 
(endothelium, basement membrane, perivascular myofibroblasts and matrix) arrive at the 
interstitial tissues is known as chemotaxis. The following agents operate as potent chemotactic 
substances or chemokinesfor neutophils: 
i) Leukotriene B4 (LT-B4), a product of lipooxygenase pathway of arachidonic acid metabolites 
ii) Components of complement system (C5a and C3a in particular) 
iii) Cytokines (Interleukins, in particular IL-8) 
iv) Soluble bacterial products (such as formylated peptides). 
Different types of leukocytes react differently to chemotactic influences. For example: 
 Most bacteria attract the PMNL 
 Foreign bodies, whether exogeneous or endogeneous like the infarct attract PMNL 
 Viruses are chemotactic for lymphocytes, usually utilising the MHC antigenon the 
surface of the infected cells. 
 Foreign cells as in a transplant attract lymphocytes and macrophages with the mediation 
of the MHC 
 Mycobacteria like tuberculosis and lepra bacilli attract macrophages and lymphocytes. 
 Allergens attract eosinophils,basophils and mast cells. 
 
1.3.1.2.2 Leukocyte activation 
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Different receptors are there in the surface of leukocytes which can sense the presence of 
microbes. The term leukocyte activation stands for a number of responses by microbial products 
or various mediators of inflammation with the engagement of receptors.. 
Leukocyte activation leads to 
 Phagocytosis 
 Production of substances which destroys phagoytosed microbes and remove dead tissues. 
 Production of mediators that enhance inflammatory response. 
1.3.1.2.3 Phagocytosis 
Phagocytosis is defined as the process of engulfment of solid particulate material by the cells 
(cell-eating). The cells performing this function are called phagocytes. There are 2 main types of 
phagocytic cells: 
i) Polymorphonuclear neutrophils (PMNs) which appear early in acute inflammatory response, 
sometimes called as microphages. 
ii) Circulating monocytes and fixed tissue mononuclear phagocytes, commonly called as 
macrophages. 
Neutrophils and macrophages on reaching the tissue spaces produce several proteolyitc 
enzymes—lysozyme, protease, collagenase, elastase, lipase, proteinase, gelatinase, 
and acid hydrolases. These enzymes degrade collagen and extracellular matrix. The microbe 
undergoes the process of phagocytosis by polymorphs and macrophages and involves 
the following 3 steps 
1. Recognition and attachment 
2. Engulfment 
3. Killing and degradation[6] [7] [8] 
 Recognition and attachment 
Phagocytosis is initiated by the expression of surface receptors on macrophages which recognise 
microorganisms: mannose receptorand scavenger receptor. The process of phagocytosis is 
further improved when the microorganisms are coated with specific proteins, opsonins, from the 
serum or they get opsonised. Opsonins create a bond between bacteria and the cell membrane of 
phagocytic cell. The major opsonins present in the serum and their matching receptors on the 
surface of phagocytic cells (PMNs or macrophages) are as under: 
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i) IgG opsoninis the Fc fragment of immunoglobulin G; it is the naturally occurring antibody in 
the serum that coats the bacteria while the PMNs possess receptors for the same. 
ii) C3b opsoninis the fragment produce by activation of complement pathway. It is strongly 
chemotactic for attracting PMNs to bacteria. 
iii) Lectins are carbohydrate-binding proteins in the plasma which bind to bacterial cell wall. 
 Engulfment 
The opsonised particle bound to the surface of phagocyte is equipped to be engulfed. This is 
accomplished by development of cytoplasmic pseudopods around the particle due to activation 
of actin filaments under cell wall, enveloping it in a phagocytic vacuole. Eventually, the plasma 
membrane enclosing the particle breaks from the cell surface so that membrane lined phagocytic 
vacuole or phagosome lies internalised and free in the cell cytoplasm. The phagosome fuses with 
one or more lysosomes of the cell and form larger  vacuole called phagolysosome. 
 Killing and degradation 
It is the stage of killing and degradation of microorganism to dispose it off justifying the function 
of phagocytes as scavenger cells. The microorganisms after being killed by antibacterial 
substances are degraded by hydrolytic enzymes. However, this mechanism fails to kill and 
degrade some bacteria like tubercle bacilli. 
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Figure 1.1 Phagocytosis 
 
 
There are intracellular metabolic pathways which generally killmicrobes by oxidative 
mechanism and less often nonoxidativepathways. They include 
i) Oxidative bactericidal mechanism by oxygen free radicals 
a) MPO-dependent 
b) MPO-independent 
ii) Oxidative bactericidal mechanism by lysosomal granules. 
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iii) Non oxidative bactericidal mechanism 
B)   Extracellular mechanisms.  
 
1.3.1.3 Systemic effects of acute inflammation 
The account of acute inflammation given up to now above is based on local tissue responses. 
However, acute inflammation is associated with systemic effects also. These include fever, 
leucocytosis and lymphangitis-lymphadenitis 
 Fever occurs due to bacteraemia. It ismediated through release of factors like 
prostaglandins, interleukin-1 and TNF-α in response to infection[9]. 
 Leucocytosis commonly follows the acute inflammatory reactions, usually in the range 
of 15,000- 20,000/μl. When the counts are higher than this with ‘shift to left’ of myeloid 
cells, the blood picture is defined as leukaemoid reaction.  
  Lymphangitis-lymphadenitis  
The lymphatics and lymph nodes that drain the inflamed tissue show reactive inflammatory 
changes in the form of lymphangitis and lymphadenitis.  
 Shock 
Enormous release of cytokine TNF-α, a mediator of inflammation, in response to severe tissue 
injury or infection results in profuse systemic vasodilatation, amplified vascular permeability and 
intravascular volume loss. The net effect of these alterations is hypotension and shock. 
 
1.3.1.4 Morphology of acute inflammation 
 Pseudomembranous inflammation. It is inflammatory response of mucous surface (oral, 
respiratory, bowel) to toxins of diphtheria or irritant gases. As a result of denudation of 
epithelium, plasma exudes on the surface where it coagulates, and along with necrosed 
epithelium, forms false membrane. 
 Ulcer. In the acute stage, there is infiltration by polymorphs with vasodilatation while long-
standing ulcers build up infiltration by lymphocytes, plasma cells and macrophages with 
associated fibroblastic proliferation and scarring. 
 Suppuration (abscess formation).When acute bacterial infection is followed by intense 
neutrophilic infiltrate in the inflamed tissue, it results in tissue necrosis. A cavity is formed 
which is called an abscess and contains purulent exudate or pus and the process of abscess 
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formation is known as suppuration. Pyogenic bacteria are the bacteria which cause 
suppuration. 
 Cellulitis. It is a diffuse inflammation of soft tissues resulting from distribution effects of 
substances like hyaluronidase released by some bacteria. 
 Bacterial infection of the blood. This includes the following 3 conditions: 
 Bacteraemia 
 Septicaemia 
 pyaemia  
 
1.3.1.5 Basic laboratory parameters in acute inflammation. 
 Acute phase reactants.The increase in C reactive protein level is consistent feature in 
inflammation. 
 Raised erythrocyte sedimentation rate. The raised reactive proteins cause increased 
clustering of red cells of rouleaux formation that determines ESR. This is prominent in 
36-48 hours 
 Leukocytosis. The total WBC count goes up from the normal of 4500-10000 percmm to 
an average of about 15000 but may go as high as 30000.[10] 
 
1.3.1.6 Pathological outcomes acute inflammation 
 Resolution. It means complete return to normal tissue following acute inflammation. 
This occurs when tissue changes are slight and the cellular changes are reversible e.g. 
Resolution in lobar pneumonia. 
  Healing. Healing by fibrosis takes place when the tissuedamagein acute inflammation is 
extensive so that there is no tissue regeneration. When tissue loss is superficial, it is 
restored by regeneration. 
 Suppuration. When the pyogenic bacteria causing acute inflammation turn out in severe 
tissue necrosis, the processleadsto suppuration. Initially, there is intense 
neutrophilicinfiltration. Subsequently, mixture of neutrophils, bacteria, fragments of 
necrotic tissue, cell debris and fibrin comprise pus which is contained in a cavity to form 
an abscess. The abscess, if not drained, may get structured by Dense fibrous tissue, and in 
time, get calcified. 
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 Chronic inflammation. Persisting or recurrent acute inflammation may progress to 
chronic inflammation in whichthe processes of inflammation and healing proceed side by 
Side. 
 
1.3.2 Chronic inflammation 
Chronic inflammation is inflammation of prolonged duration(weeks to months to years), in 
which active inflammation, tissue injury, and healing proceed simultaneously. In contrast to 
acute inflammation,which is characterised by vascular changes, edema and a predominantly 
neutrophilic infilterate, chronic inflammation is distinguished by 
 Infiltration with mononuclear cells, including macrophages,lymohocytes and 
plasma cells 
 Tissue destruction, largely induced by the products of the inflammatory cells. 
 Repair, involvingnew vessel proliferation (angiogenesis) and fibrosis. 
Acute inflammation may progress to chronic inflammation. This change occurs when the acute 
response cannot be resolved, either because of the persistence of the inflammatory agent or 
because of the intervention with the normal process of healing. 
 
1.3.2.1 Types of chronic inflammation 
 Non-specific, when the irritant substance give result to a nonspecific chronic 
inflammatory reaction with formation of granulation tissue and healing by fibrosis e.g. 
chronic osteomyelitis, chronic ulcer. 
 Specific, when the injurious agent causes a characteristic histologic tissue response e.g. 
tuberculosis, leprosy, syphilis. 
According to histopathological changes chronic inflammation can be classified as: 
 Chronic non-specific inflammation. It is characterised by non-specific inflammatory 
cell infiltration e.g. chronic osteomyelitis, lung abscess. A alternative of this type of 
chronic inflammatory response is chronic suppurative inflammation in which infiltration 
by polymorphs and abscess formation are additional features e.g. actinomycosis. 
 Chronic granulomatous inflammation. It is characterised by formation of granulomas 
e.g. tuberculosis, leprosy, syphilis, actinomycosis, sarcoidosis etc. 
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1.3.2.2 Granulomatous inflammation. 
It is a distinctive pattern of chronic inflammation characterised by the aggregates of activated 
macrophages that assume an epithelioid appearance. [11]The causes of or conditions in which 
granuloma develops are 
a. Bacterial infections. (Mycobacteria:leprosy, Tuberculosis; Spirochaete: syphilis) 
b. Fungal infections ( Coccidomycosis, Histoplasmosis, Cryptococcosis) 
c. Parasites  (ova of schistosomiasis) 
d. Foreign bodies(minerals, dust,I nsect stings, ruptured cyst in tissues etc) 
e. Immune conditions(crohn’s disease, thyroiditiss, Aschoff body of rheumatic heart 
disease) 
 
1.3.2.2.1  Pathogenesis of granuloma 
 
Figure 1.2 Pathogenesis of granuloma 
 
1.3.2.2.2   Composition of granuloma 
1. Epithelioid cells. It is one of the modified histocyte and are weakly pathogenic. 
2.  Multinucleate giant cells. They are formed by fusion of adjacent epithelioid cells and 
may have 20 or more nuclei. These nuclei may be arranged at the periphery like 
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horseshoe or ring, or are clustered at the two poles (Langhans’ giant cells), or they may 
be present centrally (foreign body giant cells). 
3. Lymphoid cells 
4. Necrosis 
5. Fibrosis. It is a feature of healing by proliferatingfibroblasts at the periphery of 
granuloma. 
 
1.3.2.2.3 Morphological features of foreign body granulomas. 
Such granulomas may develop in any organ or skin or mucous membrane where a particulate 
foreign body may enter. Visible small nodules may form. It differ from a tubercle in that the 
macrophages are smaller not typically epithelioid and the multinucleated giant cells too are not 
of the Langhan’s typebut of the foreign body type. The reaction is not organised in compact 
tubercles,but more in focal clusters of macrophages and few to many foreign body type giant 
cell. There is no caseation, there is considerable vascularisation and much heavier lymphocyte 
and plasma cell response around. Depending on the foreign body, neutrophils may also be 
associated with it. 
 
1.3.2.3 Systemic effects of chronic inflammation 
1. Fever. Invariably there is mild fever, often with loss of weight and weakness. 
2. Anaemia. chronic inflammation is accompanied by anaemia of varying degree. 
3. Leucocytosis. As in acute inflammation, chronic inflammation also has leucocytosis but 
generally there isrelative lymphocytosis in these cases. 
4. ESR. ESR is elevated in all cases of chronic inflammation. 
5. Amyloidosis. Long-term cases of chronic suppurative inflammation may cause secondary 
systemic (AA) amyloidosis. 
 
1.4 Mediators of inflammation 
Biochemical mediators released during inflammation strengthen and broadcast the inflammatory 
response. These mediators are soluble, diffusible molecules that can act locally and systemically. 
They are classified as 
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1.4.1.Cell derived mediators 
Cell derived mediators are derived from injured tissue cells or leukocytes recruited to the site of 
inflammation. Mast cells, platelets, and basophils produce the vasoactive amines serotonin and 
histamine. 
 
Histamine causes arteriolar dilation, increased capillary permeability, contraction of nonvascular 
smooth muscle, and eosinophil chemotaxis and can stimulate nociceptors responsible for the pain 
response. Its release is stimulated by the complement components C3a and C5a and by 
lysosomal proteins released from neutrophils. Histamine activity is mediated through the 
activation of one of four specific histamine receptors, designated H1, H2, H3, or H4, in target 
cells. Most histamine-induced vascular effects are mediated by H1 receptors. H2 receptors 
mediate some vascular effects but are more important for their role in histamine-induced gastric 
secretion. Less is understood about the role of H3 receptors, which may be localized to the CNS. 
H4 receptors are located on cells of hematopoietic origin, and H4 antagonists are promising drug 
candidates to treat inflammatory conditions involving mast cells and eosinophils (allergic 
conditions). 
 
Serotonin (5-hydroxytryptamine) is a vasoactive mediator similar to histamine found in mast 
cells and platelets in the GI tract and CNS. Serotonin also increases vascular permeability, dilates 
capillaries, and causes contraction of nonvascular smooth muscle. In some species, including 
rodents and domestic ruminants, serotonin may be the predominant vasoactive amine. 
 
Cytokines, including interleukins 1–10, tumor necrosis factor α (TNF-α), and interferon γ (INF-
γ) are produced mainly by macrophages and lymphocytes but can be synthesized by other cell 
types also. These polypeptides alter the activity and function of other cells to coordinate and 
control the inflammatory response. Two of the more important cytokines, interleukin-1 (IL-1) 
and TNF-α, mobilize and activate leukocytes, enhance proliferation of B and T cells and natural 
killer cell cytotoxicity, and are involved in the biologic response to endotoxins. IL-1, IL-6, and 
TNF-α mediate the acute phase response and pyrexia that may accompany infection and can 
induce systemic clinical signs, including sleep and anorexia. In the acute phase response, 
interleukins stimulate the liver to synthesize acute-phase proteins, including complement 
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components, coagulation factors, protease inhibitors, and metal-binding proteins. By increasing 
intracellular Ca2+ concentrations in leukocytes, cytokines are also important in the induction of 
PLA2. Colony-stimulating factors (GM-CSF, G-CSF, and M-CSF) are cytokines that promote 
expasnsion of neutrophil, eosinophil, and macrophage colonies in bone marrow. In chronic 
inflammation, cytokines IL-1, IL-6, and TNF-α contribute to the activation of fibroblasts and 
osteoblasts and to the release of enzymes such as collagenase and stromelysin that can cause 
cartilage and bone resorption.[12] 
 
Lipid-derived autacoids play vital roles in the inflammatory response and are a main focus of 
research into novel anti-inflammatory drugs. These compounds include the eicosanoids such as 
prostaglandins, prostacyclin, leukotrienes, and thromboxane A and the modified phospholipids 
such as platelet activating factor (PAF). Eicosanoids are synthesized from 20-carbon 
polyunsaturated fatty acids by many cells, including activated leukocytes, mast cells, and 
platelets and are therefore widely distributed. Hormones and other inflammatory mediators 
(TNF-α, bradykinin) stimulate eicosanoid production either by direct activation of PLA2, or 
indirectly by increasing intracellular Ca2+concentrations, which in turn activate the enzyme. Cell 
membrane damage can also cause an increase in intracellular Ca2+. Activated PLA2 directly 
hydrolyzes AA, which is rapidly metabolized via one of two enzyme pathways—the 
cyclooxygenase (COX) pathway leading to the formation of prostaglandin and thromboxanes, or 
the 5-lipoxygenase (5-LOX) pathway that produces the leukotrienes. 
Cyclooxygenase catalyzes the oxygenation of AA to form the cyclic endoperoxide PGG2, which 
is converted to the closely related PGH2. Both PGG2 and PGH2 are inherently unstable and 
rapidly converted to various prostaglandins, thromboxane A2 (TXA2), and prostacyclin (PGI1). 
PGE1, PGE2, and PGI1 are potent arteriolar dilators and augment the effects of other mediators 
by increasing small vein permeability. Other prostaglandins, including PGF2α and thromboxane, 
cause smooth muscle contraction and vasoconstriction. Prostaglandins sensitize nociceptors to 
pain-provoking mediators such as bradykinin and histamine and, in high concentrations, can 
directly stimulate sensory nerve endings. TXA2 is a potent platelet-aggregating agent involved in 
thrombus formation. 
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Found predominately in platelets, leukocytes, and the lungs, 5-LOX catalyzes the formation of 
unstable hydroxyperoxides from AA. These hydroxyperoxides are subsequently converted to the 
peptide leukotrienes. Leukotriene B4 (LTB4) and 5-hydroxyeicosatetranoate (5-HETE) are 
strong chemoattractants stimulating polymorphonuclear leukocyte movement. LTB4 also 
stimulates the production of cytokines in neutrophils, monocytes, and eosinophils and enhances 
the expression of C3b receptors. Other leukotrienes facilitate the release of histamine and other 
autacoids from mast cells and stimulate bronchiolar constriction and mucous secretion. In some 
species, leukotrienes C4 and D4 are more potent than histamine in contracting bronchial smooth 
muscle.[13][14] 
 
Figure 1.3 Generation of arachidonic acid metabolites and their roles in inflammation 
Platelet activating factor (PAF) is also derived from cell membrane phospholipids by the action 
of PLA2. PAF, synthesized by mast cells, platelets, neutrophils, and eosinophils, induces platelet 
aggregation and stimulates platelets to release vasoactive amines and synthesize thromboxanes. 
PAF also increases vascular permeability and causes neutrophils to aggregate and degranulate. 
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The role of free radical in inflammation is inevitable. A free radical is any species capable of 
independent existence containing one or more unpaired electrons. The unpaired electron alter the 
chemical reactivity of the molecule/atom, making it more reactive.[15][16] . 
The oxygen free radicals include; 
 superoxide anion radical (O2·-), 
 singlet oxygen (O2),  
 hydroxyl radical (·OH) and 
 perhydroxyl radical (HO2·)  
These all are together known as “reactive oxygen species” (ROS). With a single electron 
reduction several free radicals and hydrogen peroxide (H2O2) are formed. Reactive oxygen 
species are generated by oxidant enzymes, phagocytic cells, ionizing radiation etc.[11] 
Superoxide anion is  the first radical formed,  by the electron transport chain when O2 picks up a 
single electron. Radicals such as ·OH, HO2· and H2O2 are formed from O2
·–. O2·– undergoes a 
dismutation reaction catalysed by the enzyme superoxide dismutase (SOD) to form H2O2, which 
by itself is not reactive enough to cause damage to macromolecules. 
 
 
 
 
 
 
     Among 
the reactive oxygen species, ·OH is the most potent destructive radical which can react with all 
biological macromolecules (lipids, proteins, nucleic acids and carbohydrates). It is extremely 
reactive and can lead to formation of DNA-protein cross-links, single and double-strand breaks, 
base damage, lipid peroxidation and protein fragmentation . It may also be produced by ionizing 
radiation . 
H2O    →H2O·+  +  e- 
H2O  +  H2O·+  →   H3O+  + · OH 
 The cellular generation of ·OH may occur in two steps : 
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(i) Reduction of H2O2 by the Fenton reaction: 
             Fe2
+  +  H2O2    → ·OH  +  OH- +  Fe3+ 
            Cu+     +  H2O2    →  Cu2++·OH +  OH- 
(ii) Interaction of O2
·– with H2O2 by the Haber–Weiss reaction: 
             O2·-+  H2O2   →   O2  +   H2O +·OH 
The oxygen-derived free radicals have the following role in inflammation; 
 Endothelial cell damage and increased vascular permeability. 
 Activation of protease and inactivation of antiprotease which caude tissue matrix damage. 
 Damage to other cells. 
        Increased generation of free radicals and reactive oxygen species leads to several 
pathological conditions like rheumatoid arthritis, myocardial infarction, malignancy, aging, 
alzheimer’s disease, cancer etc.[17] 
The role of the free radical gas nitric oxide (NO) in inflammation is well established. NO is an 
important cell-signaling messenger in a wide range of physiologic and pathophysiologic 
processes. Small amounts of NO play a major role in maintaining resting vascular tone, 
vasodilation, and antiaggregation of platelets. In response to certain cytokines (TNF-α, IL-1) and 
other inflammatory mediators, the production of relatively high quantities of NO is stimulated. In 
larger quantity, NO is a potent vasodilator, facilitates macrophage-induced cytotoxicity, and may 
contribute to joint destruction in some types of arthritis.[18][19] 
 
1.4.2.Plasma derived mediators. 
These include the various products derived from activation and interaction of 4 interlinked 
systems: kinin, clotting, fibrinolytic and complement. Hageman factor (factor XII) of clotting 
system plays a key role in interactions of the four systems. Activation of factor XII in vivo by 
contact with basement membrane and bacterial endotoxins, and in vitro with glass or kaolin, 
leads to activation of clotting, fibrinolytic and kinin systems. In inflammation, activation of 
factor XII is brought about by contact of the factor leaking through the endothelial gaps. The 
end-products of the activated clotting, fibrinolytic and kinin systems activate the complement 
system that generate permeability factors. These permeability factors, in turn,further activate 
clotting system.[20] 
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Figure 1.4Interrelationships between the four plasma mediator systems triggered by                              
activation of factor XI 
1.4.3 Inflammatory cells 
The cells involved in acute and chronic inflammation are circulating leukocytes, plasma cells and 
tissue macrophages. 
 
1.4.3.1 Circulating leukocytes 
a.Polymorphonuclear neutrophils are acute inflammatory cells, which are involved in initial 
phagocytosis of bacteria and foreign bodies. 
b. Monocytes are chronic inflammatory cells which are involved in bacterial phagocytosis and 
regulates lymphocyte response. 
c. Lymphocytes are chronic inflammatory cells which are involved in humoral and cell mediated 
immune responses and regulate macrophage responses.. 
d. Eosinophils are chronic inflammatory cells which are involved during allergic states and 
parasitic infestations. 
e. Basophils containing electron dense molecules andfunctions as receptor for IgE molecules 
 
1.4.3.2 Plasma cells 
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These cells are bigger than lymphocytes with more abundant cytoplasm and an eccentric nucleus 
which has cart-wheel pattern of chromatin. They develop from Blymphocytes and are rich in 
RNA and Ƴ-globulin in theircytoplasm. These cells are  active in antibody synthesis. 
 
1.4.3.3 Mononuclear-Phagocyte System (Reticuloendothelial System) 
This cell system includes cells derived from 2 sources with common morphology, function and 
origin. These are as under: 
a.Blood monocytes. These comprise 4-8% of circulating leucocytes. 
b. Tissue macrophages. These include the following cells in different tissues: 
i) Macrophages in inflammation. 
ii) Histiocytes which are macrophages present in connective tissues. 
iii) Kupffer cells are macrophages of liver cells. 
iv) Alveolar macrophages (type II pneumocytes) in lungs. 
v) Macrophages/histiocytes of the bone marrow. 
vi) Tingible body cells of germinal centres of lymph nodes. 
vii) Littoral cells of splenic sinusoids. 
viii) Osteoclasts in the bones. 
ix) Microglial cells of the brain. 
x) Langerhans’ cells/dendritic histiocytes of the skin. 
xi) Hoffbauer cells of the placenta. 
xii) Mesangial cells of glomerulus. 
The mononuclear phagocytes are the scavenger cells of the body as well as participate in 
immune system of the body; their functions in inflammation are as under: 
i) Phagocytosis (cell eating) and pinocytosis (cell drinking). 
ii) Macrophages on activation by lymphokines released by T lymphocytes or by non 
immunologic stimuli elaborate a variety of biologically active substances like proteases, 
plasminogen activator,products of complement,coagulation factors etc. 
 
1.4.3.4  Giant Cells 
A few examples of multinucleate giant cells exist in normal tissues (e.g. osteoclasts in the bones, 
trophoblasts in placenta, megakaryocytes in the bone marrow). However, in chronic 
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inflammation when the macrophages fail to deal with particles to be removed, they fuse together 
and form multinucleated giant cells. Besides, morphologically distinct giant cells appear in some 
tumours also. Some of the common types of giant cells are  
i) Foreign body giant cells. 
ii) Langhans’ giant cells.. 
iii) Touton giant cells.. 
iv) Aschoff giant cells.[21][22] 
 
 
Figure 1.5 Inflammatory cells 
 
1.5 Pain 
Pain is a multidimensional occurrence that is essential for the maintenance and preservation of an 
individual. It warns of the danger of bodily harm and alerts to trauma and injury. Pain is a 
specific enteroceptive sensation; it can be perceived as arising from a particular portion of the 
body, its temporal properties can be detailed, it can be differentiated qualitatively (for example, 
as stinging, pricking, burning, throbbing, dull or aching), and it  involves dedicated subsets of 
peripheral and central neurons. The experience of pain has a distinctly unpleasant character, that 
is, an affective or motivational aspect that can be distinguished from its discriminative sensory 
aspects and from the long-term emotional experience of ‘suffering’. The unpleasantness ranges 
in intensity from the discomfort of a cold room, fatigued muscles or colonic tension to the 
excruciating agony of a severe burn, toothache, gallstone or migraine.  
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Under normal circumstances, primary afferent pain fibres activate particular central 
pathways that engage protective mechanisms at many functional levels: autonomic, homeostatic, 
motor, behavioural and mnemonic. However, injury or disease can change the balance of this 
system and result in persistent, pathological pain. Analgesic substances, such as aspirin and 
morphine, which interact with the transmitters and modulators of the pain system are helpful for 
many people with pain, but there is a great need for the development of better methods for the 
lessening and control of both acute (immediate) and chronic (long-term, pathological) pain.[23] 
During the process of inflammation, a mixture of inflammatory mediators such as 
peptides (bradykinin), lipids (prostaglandins), neurotransmitters (ATP), protons and 
neurotrophins (NGF) are released.The release of neuropeptides from peripheral neurones 
supports plasma extravasation of further mediators and chemoattraction of inflammatory cells, a 
process called as “neurogenic inflammation”. The sensitisation of the primary afferent neurones 
by local inflammatory mediators can occur by a direct action on the sensory neurones, or it can 
involve an indirect action on non-neuronal cells, especially but not exclusively on immune cells, 
from which further inflammatory mediators can then be released.[24] 
 
1.5.1 Pain pathways 
          Nociceptors, or pain receptors, are free nerve endings that respond to painful stimuli which 
transmit information to the brain. Pain perception occurs when  electrical, thermal, mechanical, 
biological and chemical stimuli  are transmitted to the spinal cord and then to the central areas of 
the brain. Pain impulses travel to the dorsal horn of the spine, where they synapse with dorsal 
horn neurons in the substantia gelatinosa and then ascend to the brain. The basic sensation of 
pain occurs at the thalamus. It continues to the limbic system and the cerebral cortex, where pain 
is perceived and interpreted.[25] 
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Figure 1.6 Pain pathway 
1.5.2 Pain theories: 
 Specificity theory. 
 Pattern theory. 
 Gate control theory. 
 Anodal blocking theory and, 
 Central inhibition theory. 
 
1) Specificity Theory: 
It proposes that a mosaic of specific pain receptors in body tissue projects to a main center in the 
brain. It maintain that free nerve endings are pain receptors which generate pain impulses that are 
carried by A-delta and C-fibers in peripheral nerves and by the lateral spinothalamic tract in the 
spinal cord to a pain center in the thalamus."Pain receptor" implies that stimulation of one type 
of receptor elicits a single psychological or physiological response. 
2) Pattern Theory: 
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               According to this theory, pain is the result of the stimulation of certain nerve impulses 
that form a pattern and are then brought together and deserted into the spinal cord as a lump sum 
of pain, a process called “central summation.” 
 
3) Gate Control Theory: 
               Melzack and Wall published this theory in 1965. According to this theory, a mechanism 
in the brain acts as a gate to increase or decrease the flow of nerve impulses from the peripheral 
fibers to the Central nervous system. An “open” gate allows the flow of nerve impulses, and the 
brain can perceive pain. A “closed” gate does not allow flow of nerve impulses, decreasing the 
perception of pain. 
 
4) Anodal Blocking Theory:  
               This theory proposes maintaining the absolute refractory period in the nerve by rapidly 
and repeatedly stimulating the nerve fiber, thus preventing pain impulses from being transmitted. 
 
5) Central Inhibition Theory: 
              It suggests that large-fiber and small-fiber activity do not result in presynaptic effects of 
opposite polarity as suggested by the gate control theory. The concept of inhibitory balance 
depends on minor inhibitory feedback from small fiber input that activates the nociceptive 
marginal neuron and major inhibitory feedback to the marginal neuron from large non-
nociceptive fibers. Modulation of pain producing input thus depends on the balance between 
large fiber and small fiber activity via a postsynaptic inhibitory mechanism acting on the 
nociceptive relay neurons.[26] 
 
1.6 Anti-inflammatory drugs and analgesics 
              Anti-inflammatory drugs are the drugs which are used for the treatment of 
inflammation. They are mainly used in infections like rheumatoid arthritis and gout . Analgesic 
is a drug that selectively relieves pain by acting in the CNS or on peripheral pain mechanisms, 
without significantly altering consciousness.  
Analgesics are divided into two groups; 
 Opioid / Narcotic / Morphine like analgesics 
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 Nonopioid / Non-narcotic /Antipyretic or anti-inflammatory analgesics. 
1.6.1 Narcotic analgesics: 
1.6.1.1 Classification: 
I) Narcotic Agonist Analgesics 
          i) Natural opium alkaloids: Morphine, codeine 
         ii) Semi synthetic opiates: Diacetylmorphine, Pholcodeine, Ethylmorphine                                      
        iii) Synthetic opioids: Pethidine, Fentanyl, Methadone, Tramadol 
II) Narcotic Agonist-Antagonist Analgesics 
         i) Phenanthrenes: Buprenorphine, Nalbuphine 
        ii) Morphinan: Butorphanol 
       iii) Benzomorphans: Phenazocine , Pentazocine 
 
1.6.1.2 General mechanism Of Action Of Narcotic Analgesics: 
            It exerts its effects by interacting with opioid receptors (μ, κ and δ ) located on 
prejunctional neurons. Activation of opioid receptor reduces intracellular cAMP formation and 
opens potasium channels or suppresses voltage gated N type Calcium channels. These actions 
leads to neuronal hyperpolarisation and reduced availability Of intracellular calcium, decreased 
neurotransmitter release by CNS and myenteric neurons.[27] 
 
Figure 1.7 Opioid receptor transducer mechanism 
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1.6.1.3Adverse Effects associated with opiods. 
The various adverse effects associated with opioids include respiratory depression, drowsiness, 
nausea, vomiting, endocrine disturbances, tolerance to analgesic effect, physical dependence, 
abuse potential and interaction with CNS depressant drugs. [28] 
1.6.2 Nonsteroidal Anti-inflammatory Drugs and Antipyretic-Analgesics : 
1.6.2.1 Classification: 
A) Nonselective COX inhibitor 
      1. Salicylates: Aspirin. 
      2. Propionic acid derivatives: Ibuprofen , Ketoprofen. 
      3. Fenamates: Mephenamic acid. 
      4. Oxicams: Piroxicam, Tenoxicam. 
      5. Pyrazolones: Phenylbutazone, Oxyphenbutazone. 
      6. Indole derivatives: Indomethacin, Sulindac. 
     7. Aryl-acetic acid derivatives: Diclofenac. 
     8. Pyyrrolo-pyrrole derivatives: Ketorolac. 
B) Preferential COX-2 Inhibitors: Nimesulide. 
C) Selective COX-2 Inhibitors: Celecoxib, Etoricoxib. 
D) Analgesic-antipyretics with poor anti-inflammatory action. 
     1. Paraaminophenol derivative: Paracetamol. 
     2. Pyrazolone derivatives: Metamizol, Propiphenazone. 
     3. Benzoxazocine derivative:  Nefopam. 
 
1.6.2.2 General mechanism Of Action Of NSAIDs: 
            Nonsteroidal anti-inflammatory drugs exert their anti-inflammatory effect through 
inhibition of  cyclooxygenase, which is the enzyme catalyzing the transformation of arachidonic 
acid to prostaglandins and thromboxanes.NSAIDs also inhibit expression of cell adhesion 
molecules and directly inhibit activation and functions of neutrophils.[29] 
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Figure 1.8 : Mechanism of action of NSAIDs. 
 
1.6.2.3 Adverse effects of NSAID Therapy 
NSAIDs produces various adverse effects as it interfere with various pathways that maintain 
homeostasis.The manifestations are as follows[30] 
 
Table 1.1 Adverse drug reactions of NSAIDs 
SYSTEM MANIFESTATIONS 
GI Abdominal pain, nausea, anorexia, gastric erosions, anemia, 
GI hemorrhage, perforation, diarrhea 
Renal Salt and water retention, hyperkalemia, Decreased 
effectiveness of diuretic and antihypertensive medications 
CNS Vertigo, dizziness, lowering of seizure threshold 
,hyperventilation, depression. 
Platelets Inhibited platelet activation 
Uterus prolongation of gestation and possible prolongation of labor 
Hypersensitivity Vasomotor rhinitis, angioedema, asthma, urticaria, flushing, 
hypotension, shock 
Vascular Closure of ductus arteriosus 
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1.7 Cyclo oxygenase as a drug target 
Three isoforms of COXs have been identified. Cyclooxygenase-1 (COX-1) is a glycoprotein of 
71kDa, which is constitutively expressed in different tissues. COX-1 is encoded by a gene on 
chromosome 9 and plays a role in tissue homeostasis by modulating several cellular processes 
ranging from cell proliferation to angiogenesis or platelet aggregation due to thromboxane 
production . Cyclooxygenase-2 (COX-2) is the inducible isoform, which is regulated by growth 
factors and different cytokines such as IL1β, IL6, or TNFα , therefore overexpressed during 
inflammation. The COX-2 gene is located on chromosome 1 and its promoter displays an NFκB 
response element as well as other cytokine-dependent (i.e., IL6) response elements . The protein 
shows a 60% homology with COX-1 [31]; in addition, COX-2 presents a C-terminal extension 
and a different binding site for NSAIDs, which makes COX-2 a preferential target compared to 
COX-1, thus being specifically inhibited at lower doses . Finally, COX-3 has been identified as a 
splice variant of COX-1, and it is present mainly in brain and spinal cord . Currently, the role of 
COX-3 is not known. Some pieces of evidence suggest a possible role in pain sensitivity, based 
on studies focused on the mechanism of action of acetaminophen (paracetamol), recently evoked 
as a selective inhibitor of COX-3[32]. 
The COX molecule consists of three independent folding units: an epidermal growth 
factor-like domain, a membrane binding site, and an enzymatic domain . The active COX site is 
a hydrophobic channel with a series of amino acids. Aspirin binds irreversibly to serine 580 by 
acetylation, whereas most other NSAIDs bind sterically and reversibly to Tyrosine 385 or 
Arginine 120, blocking the COX action resulting in the alleviation  of pro-inflammatory ARA 
metabolites, and in particular, prostaglandin E2(PGE2)[33]. The use of NSAIDs is often limited 
by side effects emanating from disrupting the levels of these protective COX metabolites. 
Following the discovery of a second form of COX enzyme (COX-2) ,COX-2 selective inhibitors 
(coxibs) such as celecoxib and rofecoxib  were subsequently developed in an effort to 
circumvent these problems. Coxibs are effective against inflammation and pain, with 
comparatively less risk of severe GI toxicity associated with conventional NSAIDs. However, 
there are safety concerns with coxib use due to an increase in the risk of cardiovascular events 
associated with the imbalance of the PGI2 and thromboxane (TXA2) metabolite levels . 
Inhibition of COX-1 decreases platelet-derivedTXA2, an eicosanoid which functions as a 
vasoconstrictor and facilitates platelet aggregation. Selective inhibition of COX-2 affects the 
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PGI2/TXA2 ratio to favor TXA2, increasing the risk of mortality from ischemic heart 
disease.Recently, a metabolomic approach to study the relationship between adverse 
cardiovascular eventsand the use of rofecoxib suggested that this drug acts, in part,through 
accumulation of 20-hydroxyeicosatetraenoic acid (20-HETE) which is a potent vasoconstrictor 
among ARA metabolites. Treatment of inflammation and pain constitutes significant medical 
needs because more people are prone to these conditions than any other disease state. Thus, there 
is a growing demand for safer but efficacious NSAIDs or coxibs . Upcoming concepts and 
approaches forthe treatment of inflammation and pain have moved towards simultaneously 
targeting multiple enzymes in the ARA cascade through combination therapy and multi target 
inhibitors such as dual inhibitors with the aim of overcoming the risks in single enzyme or 
pathway inhibition[34] 
 
1.8 Inflammation and cancer 
Inflammatory conditions in selected organs augment the risk of cancer. An inflammatory 
component is present also in the microenvironment of tumors which are not epidemiologically 
related to inflammation[35]. Over expression of COX-2 has been detected in a number of tumors, 
such as colorectal breast as well as pancreatic and lung cancers which can be correlated with a 
poor prognosis. Moreover, over expression of COX-2 has been reported in hematological cancer 
models like RAJI (Burkitt’s lymphoma) and U937 (acute promonocytic leukemia)  as well as in 
patient’s blast cells. Data suggested that COX-2 may play a role in different steps of cancer 
progression, by increasing proliferation of mutated cells, thus favoring tumor promotion as well 
as by affecting programmed cell death and affecting the efficacy of anticancer therapies to be, 
finally, concerned in metastasis formation, for example, by affecting apoptosis induced by loss of 
cell anchorage (anoikis). Combination of preferential orselective COX-2 inhibitors with anti-
cancer agents already used in clinics were tested with the goal to improve the efficiency of anti-
cancer protocols. 
 
1.9 In silico drug design 
Pharmaceutical research has successfully incorporated a wealth of molecular modelling methods, 
within a variety of drug discovery programs, to study complex biological and chemical systems. 
The integration of computational and experimental strategies has been of great value in the 
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identification and development of novel promising compounds. Broadly used in modern drug 
design, molecular docking methods explore the ligand conformations adopted within the binding 
sites of macromolecular targets. This approach also estimates the ligand-receptor binding free 
energy by evaluating critical phenomena involved in theintermolecular recognition process.  
 
Two approaches are used in drug design 
1.Structure based drug design 
2.Ligand based drug design 
 
1.9.1 Structure Based drug design 
If reliable information about the 3-D structure and active sites of the target protein can be 
obtained from X-ray crystallography, nuclear magnetic resonance, or 3-D structure databases, 
and integrated into a computer model, compounds binding to the target can be designed. This 
approach is called “structure-based drug design”. Commonly used techniques in this approach 
are docking and molecular dynamics simulation. Potent ligands can be found by screening a 
molecule database with docking software. Molecular dynamics simulation can be useful to 
determine not only how a molecule interacts with the target protein, but also to determine some 
other properties of the molecule itself, such as membrane permeability.[36] 
 
1.9.2 Ligand Based drug Design 
When the receptor structure is unknown but the ligand structures are known, a ligand based 
approach is used. An extension of the QSAR approach is used to study the active ligands, also 
known as pharmacophore based drug design. The pharmacophore refers to an ensemble of steric 
and electronic features that enables it to exhibit specific biological activity.generally, this method 
depend on the application of descriptors of molecular structure and properties, including 
structure or- descriptor- based queries, finger print queries, clustering and partitioning [37]. 
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Figure1.9 Workflow of various approaches in in silico drug design 
 
Heterocycles always remain as a potential scaffold with variety of pharmacological significance. 
Numerous research reports have indicated the coumarin nucleus as a potential candidate for 
development of anti-inflammatory drugs.[37]As an important class of compounds, quinolin-2-
ones are isomeric to 4-quinolones and isosteric to coumarins. The compounds that have quinolin-
2-one moiety are associated with biologic activities such as antibacterial, anticancer, antiviral, 
cardiotonic, and N-methyl-D-aspartate receptor inhibitor functions, among others. Thiazole, 
oxazoles ,N-substituted piperazines and aminopyridine containing scaffolds are proven to be  
promising entities with good anti inflammatory, analgesic and antioxidant potential. In the 
current study, based on the rational approach, various analogs of 2-quinolones were designed for 
binding to COX2 enzyme with less ulcerogenic effects. 
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CHAPTER 2 
LITERATURE REVIEW 
 
Quinolinone derivatives 
1. Lan et al.,(2014)[39]; synthesised  and evaluated the analgesic potential of 3,4-dihydroxy-
2(1H)-quinolinone derivatives as novel sigma-1 receptor antagonists. The compounds were 
evaluated in vitro in sigma-1 and sigma-2 receptor-binding assays in guinea pig brain 
membranes.7-(3-(piperidin-1-yl)propoxy)-1-(4-fluorobenzyl)-3,4-dihydro-2(1H) quinolinone (1) 
was profiled with highest affinity and greatest selectivity which possess a high binding constant 
for sigma-1 receptor and high sigma-1/2 selectivity (1066-fold). In formalin test, compound (1) 
produced dose-dependent anti-nociception in both phases with ED50 values 49.4 ± 4.1 and 50.5 
±2.5 mg/kg for phases I and II, respectively. 
N
O
F
O N
 
(1) 
 
2.Kumar  et al.,(2014)[40]; synthesised and evaluated the antimicrobial and anti-inflammatory 
activity of isoxazolineincorporared 2 quinolones.Among the synthesised compounds compound 
(2) and (3) showed maximum percentage inhibition of edema volume at 4th hour when compared 
to the standard drug diclofenac sodium in the carrageenan induced paw edema model at dose of 
200mg/kg 
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      (2)      (3) 
 
3.Pudlo et al., (2014)[41]; designed, synthesised and evaluated hybrids of quinolinone-
benzylpiperideine as novel acetylcholinesterase inhibitors and antioxidants. Among the 
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synthesised compound (4) was found to possess high free radical scavenging activity in DPPH 
(EC50 = 12.2 µM) and superoxide anion assays (EC50 =138.8µM) 
N
H
N
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O
CH3
Cl
O
 
(4) 
 
4.Nitesh et al.,(2012)[42]; elucidated the anticancer activity of synthesized 2-quinolone 
derivatives without N-methyl or 3-aryl substitution. Significant cytotoxicity was observed in 
MCF-7 cells treated with (5) and (6).Both the derivatives’ treatment showed damage to the 
DNA. In vivo studies for (5) and (6)were performed at two doses 100 and 200 mg/kg using 
Ehrlich ascites carcinoma (liquid) and Dalton lymphoma ascites (solid) models. Both derivatives 
showed a significant reduction in the tumor progression by increasing the mean life span and by 
improving the haematological profile and antioxidant status of the liver in a liquid tumor model. 
More prominent effect was observed in a solid tumor model by reduction in solid tumor weight 
and tumour volume. The CTC50 of (5) and (6) were found to be, 83.04µM and 22.04 µM 
respectively 
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(5)       (6) 
5.Jayashree et al.,(2010)[43];  designed and synthesised a series of 2-quinolone derivatives as 
anti oxidants and antimicrobials. Based on the docking stimulation and QSAR studies, the 7-
amino-4-methylquinolin-2(1H)-one parent compound and its carboxamides) were synthesized 
using Conrad  Limpach synthesis. Among the compounds synthesised compound (7) showed 
highest anti oxidant activity with IC50 170.01 µg/mL. 
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6.Sankaran et al., (2010)[44];  synthesised and conducted antioxidant and toxicological study of 
novel pyrimido quinolone derivatives from 4-hydroxy-3-acyl quinolin-2-one. They were 
screened for their in vitro antioxidant activities against radical scavenging capacity using DPPH, 
Trolox equivalent antioxidant capacity (TEAC), total antioxidant activity by FRAP, superoxide 
radical scavenging activity, metal chelating activity and nitric oxide scavenging activity. Among 
the compounds screened, (8) and (9) exhibited significant antioxidant activities. 
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   (8)                    (9) 
7.Detsi et al.,(2007)[45];  designed and synthesised a  series of N-substituted-quinolinone-3-
aminoamides and their hybrids containing the R-lipoic acid functionality as potential 
bifunctional agents combining antioxidant and anti-inflammatory activity. The compounds were 
evaluated for their antioxidant activity and for their ability to inhibit in vitro lipoxygenase as well 
as for their anti-inflammatory activity in vivo. Among the compounds synthesised compound 
(10) was found to be most potent anti-inflammatory agent with 85.3% inhibition of paw edema 
volume in carrageenan induced paw edema method. 
N O
OH
CH3
N
H
O
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(10) 
Piperazine derivatives 
8.Patel et al.,(2016)[46]; established the antioxidant and anti cancer potential of newly 
synthesised chrysin-piperazine conjugates. Among the synthesised compounds, (11) was found 
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to be the most potent antioxidant giving an IC50 of 20.30 µg/mL and 5.62 µg/mL in DPPH and 
ABTS assay method respectively. 
O
O
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N
OH  
(11) 
9.Silva et al.,(2015)[47]; investigated the anti-nociceptive and anti-inflammatory effects of 
piperazine derivative 4-[(1-phenyl-1H-pyrazol-4-yl) methyl]1-piperazine carboxylic acid ethyl 
ester (12) and the involvement of the serotonergic pathway. In the formalin test, treatments with 
this compound (15 and 30 mg/kg p.o.) reduced the licking time in both neurogenic and 
inflammatory phases. In the tail flick and hot plate tests, (12) treatment increased latency to 
thermal stimulus and in the carrageenan-induced paw edema test, at the doses of 15 and 30 
mg/kg reduced the edema at all tested time points, while the dose of 7.5 mg/kg reduced the 
edema only for the first hour.Compound (12) (30 mg/kg p.o.) reduced both cell migration and 
protein exudation in the carrageenan-induced pleurisy test. 
N
N
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N
N
 
(12) 
10.Ghorbani et al., (2015)[48]; synthesised a series of  novel piperazine analogues bearing 
quinolin-8yloxy-butan-1-ones/pyridine-2-yloxy-Ethanone. The analogues were evaluated for in 
vitro antioxidant activity against DPPH and ferrous ion radical scavenging activities and anti-
inflammatory activity by inhibition of Vipera russelli venom (PLA2) and gastric K+/H+ ATPase 
activities.It was found  that pyridine ring with phenyl and nitro-phenyl group of (13) and (14) 
showed potent inhibition against all the assays 
              O
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       (13)                  (14) 
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11.Mistry et al., (2015)[49] synthesised new Mannich base series of piperazine linked berberine 
analogues and were evaluated for antioxidant and anti-cancer activities. The radical scavenging 
potential of the final derivatives was found excellent with IC50s, <13 lg/mL and<8 lg/mL in 
DPPH and ABTS assay, respectively, whereas some analogues showed significant Fe+3 
reducing power with absorption at around 2 nmin the FRAP assay.compound(15) was found to 
be more potent. Anticancer effects of titled compounds were inspected against cervical cancer 
cell line Hela and Caski adapting SRB assay, in which the analogues presented <6 lg/mL of 
IC50s, and>30 of therapeutic indices, thus exerting low cytotoxic values against Malin–Darby 
canine kidney (MDCK) cell lines at CC50s >125 lg/mL. 
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O O
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(15) 
12.Andonova et al., (2014)[50]; synthesised  and evaluated the  antioxidant activity of some 1-
aryl/aralkylpiperazine derivatives with xanthine moiety at N4. All compounds were in vitro 
screened for their activity as antioxidants using DPPH, and FRAP methods. The antioxidant 
activity of the studied compounds against lipid peroxidation was also measured. The highest 
antioxidant activity was demonstrated by compound (16) with IC50 values . 189.42 µmol/L
2,3.45 
µmol/L2and173.99 µmol/L2  for DPPH, ABTS and FRAP assays respectively. 
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13.Mohan et al., (2014)[51]; synthesised and evaluated the antibacterial, anthelmintic and anti-
Inflammatory activity of some novel methylpyrimidinesulfonylpiperazine derivatives. 
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Compounds (17)and (18) were proven to be good anti-inflammatory agents at adose 100mg/kg in 
carrageenan induced paw edema method. 
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   (17)       (18) 
 
14.Girish et al.,(2012)[52];  synthesised a series of novel 6-methoxy-2-(piperazin-1-yl)-4H-
chromen-4-one and 5,7-dimethoxy-2-(piperazin-1-ylmethyl)-4H-chromen-4-one derivatives of 
biological interest and screened for their pro-inflammatory cytokines (TNF-α and IL-6) and 
antimicrobial activity (antibacterial and antifungal). Among all the compound screened, the 
compounds (19)(82%TNF-α and 87 %IL-6 inhibitory activities ) and (20) (85%TNF-α and 
91 %IL-6 inhibitory activities) were found to have promising anti-inflammatory activity  at 
concentration of 10 μM with reference to standard dexamethasone (71% TNF-a and 84% IL-6 
inhibitory activities at 1 μM)  
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  (19)       (20) 
15.Kimura et al., (2004)[53]; synthesised a new series of diphenylalkylpiperazine derivatives 
with high affinities for the dopamine transporter (DAT), which were modified at both the 
diphenylalkyl moiety and the phenyl ring in the phenylamino moiety of 1-[4,4-bis(4-
fluorophenyl)butyl]-4-[2- hydroxy-3-(phenylamino)propyl]piperazine  and was evaluated for 
their inhibitory activities against auto-oxidative lipid peroxidation in canine brain 
homogenates.The 4-hydroxyphenyl derivative (21) showed the most potent anti-oxidative 
activity with an IC50 value of 0.32 lM, exhibiting approximately 5-fold more potent activity than 
a-tocopherol. 
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16.Renard et al.,(2014)[54]; synthesised a series of analogs of nimesulide resulting from isosteric 
replacement of the nitrobenzene ring by the pyridine nucleus, was synthesized and their ability to 
inhibit both cyclooxygenases (COXs) isoforms was evaluated in vitro using a human whole 
blood model Among the synthesised compounds, those bearing a bulky halogen atom 
(compounds 22 and 23) displayed the most important activity (COX- 2 IC50 values for 
(22)and(23): 0.12 and 0.26 mM, respectively) and selectivity against COX-2 (COX-2 selectivity 
ratio for 7 and 19c: 7.48 and 7.46, respectively) 
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17.G Nigade et al., (2012)[55]; synthesised a series of  heterocyclic compounds containing 
pyridine nucleus and was evaluated for its analgesic activity by using Eddy’s hot plate method 
and formalin induced licking  test. Among the compounds synthesised compound (24)was found 
to be produce the highest inhibition of inflammation at a dose 25mg/kg 
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18.Ranga et al.,(2012)[56]; synthesised and evaluated new thiazolidinylanalogs containing 
pyridine ring and QSAR and molecular docking studies were performed for the same. Among 
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the compounds synthesised compound (25) exhibited the highest docking score and was also 
found to be the most active compound of the series with an dual anti-inflammatory and analgesic 
activity at a dose 10mg/kg p.o 
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19. G.A. El-Achkar et al.,(2015)[57]; investigated the in vitro and in vivo effects of two novel 
thiazole derivatives(26) (N-[4-(4-hydroxy-3-methoxyphenyl)- 1,3-thiazol-2-yl]acetamide) and 
(27)(4-(2-amino-1,3-thiazol-4-yl)-2-methoxyphenol)on prostaglandin E2 (PGE2) productionand 
COX activity in inflammatory settings. The results revealed the potent inhibition of both 
compound (25) (IC50 9.01±0.01 mM) and (26) (IC50 11.65±0.20 mM) on COX-2-dependent 
PGE2 production.It was found that compound (26) is a specific inhibitor of COX-1 
withIC50(5.56*10
-8±2.26*10-8mM), whereas compound (27)did not affect COX-1 using  HEK- 
293  cells stably over-expressing COX-1and human blood platelets.Both compounds produced 
inflammatory effect in the dorsal air pouch model of inflammation 
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20.Prakash et al.,(2015)[58]; synthesised series of novel 3-(4-(2-(substituted benzylideneamino) 
thiazol-4-yl)phenylimino)-1-((dimethylamino)methyl)-5-fluoroindolin-2-one Schiff and Mannich 
base derivatives and evaluated for their analgesic anti-inflammatory , antimicrobial and 
ulcerogenic potential.Among the synthesised compounds (28) and (29) found to be more potent  
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(28)       (29) 
21.Khillare et al.,(2014)[59]; synthesised and evaluated  new trisubstitutedpyrazoles bearing 
thiazolyl and thiazolidinonyl moieties from 5-acetyl thiazoles as starting materials. Among the 
synthesised compounds compounds, after 4thanf 6th hour (30) showed good  anti-inflammatory at 
a dose equimolar to 50mg/kg of celcoxib. 
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(30) 
22.Aggarwal et al.,(2013)[60]; synthesised a  series of novel 2-(5-hydroxy-5-
trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles and evaluated for 
their anti-inflammatory and ant microbial activities. Among the synthesised compounds, 
Compounds (31)and(32) showed the highest (83 and 86%, respectively) anti-inflammatory 
activity, when compared to standard anti-inflammatory drug indomethacin (94%). 
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23.Helal et al.,(2013)[61]; synthesised and evaluated the anti- inflammatory activity of some 
novel thiazole compounds. Furo[2,3-d]thiazol-5(2H)-one (33) was obtained from reaction of 
thiosemicarbazone derivative with diethyl acetylene dicarboxylate and  4-(4-Morpholino phenyl) 
thiazol-2-amino (34) was obtained via the reaction of acetophenone derivative with thiourea in 
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presence of iodine. Among the synthesised compound these compounds showed a higher degree 
of inhibition of paw edema with a percent inhibition of 85 and 87 respectively. 
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24. R.N Sharma et al.,(2009)[62]; applied  an analogue based drug design approach for 
synthesising 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents. Among the 
compounds synthesised compound (35) emerged as the most potent compound in carrageenan 
induced inflammatory model with a percentage inhibition of 60.8% at a dose 50mg/kg 
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25.Holla et al. (2003)[63]; reported different series of arylaminothiazoles, arylidene/5-aryl-2-
furfurylidene hydrazine thiazoles and screened them for their antibacterial and anti-inflammatory 
activities. Two of the newly synthesized compounds (36) and (37)  showed anti-inflammatory 
activity comparable with that of ibuprofen at a dose 20mg/kg i.p 
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26.Mathew et al., (2012)[64]; synthesised some novel 2,4-diphenyloxazole derivatives and 
evaluated theirin vitro antioxidant and anticancer activity. Among the synthesised compounds, 
(38) showed nitric oxide scavenging activity with IC50 at 461.28 mg/mL. 
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27.Zhou et al.,(2009)[65]; designed and synthesized a  series of 4,5-diaryloxazole analogs as a 
novel anti-inflammatory drug and the interaction between oxaprozin and cyclooxygenase- 2 was 
studied by docking method to improve the biological activity and reduce the gastrointestinal side 
effects of oxaprozin. Among the compounds analysed, 3-(4-(4-fluorophenyl)-5-(4-
aminosulfonyl-3-fluorophenyl)-oxazole-2-yl) propanoic acid (39), was selected for synthesis and 
pharmacological evaluation.Compound39 showed anti-inflammatory activity up to 31.7% at 80 
mg/kg after 3 h of drug treatment in carrageenan induced paw edema and showed an inhibitory 
value of up to 54.0% at 100 mg/kg over 15 min in acetic acid induced writhing response test in 
mice . 
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CHAPTER 3 
AIM AND OBJECTIVES 
Inflammation is a universal host defence process involving a complex network of cell-cell 
mediator and tissue interactions. Inflammatory diseases cover a broad spectrum of conditions 
including autoimmune diseases (eg:rheumatoid arthritis),osteoarthritis, inflammatory bowel 
disease, multiple sclerosis, asthma, chronic obstructive pulmonary disease, allergic rhinitis, 
infectious diseases, various types of cancers and cardiovascular diseases. Until a few years ago, 
inflammatory disorders were treated primarily with relatively non selective anti- inflammatory 
drugs such as such as corticosteroids and various NSAIDs , however, now a days several 
mediator antagonists alone or in combination and gene therapy are also bring tried. 
Research in last few decades has shown that inflammation is regulated by a large number of pro 
and anti-inflammatory mediators. Advent of genomic era has emphasised the role of altered gene 
expression as fundamental to aetiology of inflammation and immune disorders..Efforts to 
develop new safer and more effective anti-inflammatory drugs are based on the role of key 
mediators identified as the key culprits in this condition. Inhibitors which specifically interfere 
with different components of different intracellular signalling pathways or inhibit the activation 
of transcription factors responsible for the expression of disease related genes have applications 
as novel therapeutic agents in inflammation. Inorder to search newer inhibitors of inflammatory 
signals, several chemical entities are being cloned with the help of in silico drug design 
stratergies.  
Quinolinones are the conventional scaffolds with antibacterial activity.As an important class of 
compounds, quinolin-2-ones are isomeric to 4-quinolones and isosteric to coumarins. The 
compounds that have 2-quinolone moiety are associated with interesting biologic activities such 
as antibacterial, anticancer, antiviral, cardiotonic, and N-methyl-D-aspartate receptor inhibitor 
functions, among others. This study aimed to design, synthesis and evaluate various quinolin-2-
one analogs, which contain thiazole, oxazole, aminopyridine, methyl piperazine and 
phenylpiperazine substitutions. The study also targeted in designing a molecule which is a 
selective COX2 inhibitor and thus can overcome  the side effects caused by existing NSAIDs. 
 The study focuses on designing compounds with quinolin-2-one nucleus as potent COX-2 
inhibitor and thereby evaluating in vitro antioxidant and in vivo anti-inflammatory and analgesic 
activity followed by evaluating the ulcerogenic potential of the compounds.  
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CHAPTER 4 
PLAN OF WORK 
The plan of present work is  
 Review of literature and scientific survey of the title compounds. 
 Selection of target protein and ligand nucleus for anti-inflammatory and analgesic 
activity assessment. 
 Design of molecules based on selected nucleus by molecular modeling software and 
determination of  potent molecule by docking study. 
 To synthesize quinolin-2-one analogs based on the reported literature procedure. 
 To check the purity of the recrystallized compounds by melting point, TLC. 
 Characterization of synthesized compounds by various analytical techniques like UV, 
FT-IR, 1H-NMR and Mass spectral analysis. 
 Screening of synthesized compounds for in vitro anti-oxidant activity  
 DPPH radical scavenging assay 
 ABTS method. 
 Screening of synthesized compounds for their 
 In vivo anti-inflammatory activity. 
 Carrageenan induced paw edema method 
 Cotton Pellet induced granuloma method 
 In vivo analgesic activity 
 Eddy’s hot plate method 
 Acetic acid induced writhing method 
 Ulcerogenic potential studies 
 Antibacterial activity 
 
.  
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CHAPTER 5 
EXPERIMENTAL WORK (CHEMISTRY) 
5.1 Materials 
The chemicals, reagents, solvents, glassware and other necessary things which are used for the 
synthesis, purchased from various companies (Hi media and Spectrochem) stored in well closed 
container. Stored chemicals were used without further purification. 
5.2 Methods 
5.2.1 Docking studies 
5.2.1.1 Autodock 
Autodock is a suite of C programs used to simulate interactions between small flexible ligands 
and macromolecules of known structure. Docking is achieved through a search of 
conformational space using a Lamarckian genetic algorithm coupled with energy assessments 
using auto dock method. The combination of these two functions produces a family of molecular 
coordinates detailing possible docked ligand conformations which can then be used as a starting 
point for theoretical ligand design and study. Confidence in the docked conformation is 
represented by an energy value based on both quantum and molecular mechanical modelling of 
atomic forces. The success of a docking program depends on the Lamarckian genetic 
algorithm.[66] 
 Lamarckian genetic algorithm  
The vast majority of genetic algorithms mimics the major characteristics of darwinian evolution 
and apply mendelian genetics. This is illustrated on the oneway transfer of information from the 
genotype to the phenotype. However, in those cases where an inverse mapping function exists, 
one which yields a genotype from a given phenotype, it is possible to finish a local search by 
replacing the individual with the result of the local search. This is called the Lamarckian genetic 
algorithm (LGA). The most important issues arising in hybrids of local search (LS) techniques 
with the GA revolve around the developmental mapping, which transforms genotypic 
representations into phenotypic ones. The genotypic space is defined in terms of the genetic 
operator’s mutation and cross over in our experiments by which parents of one generation are 
perturbed. The phenotypic space is defined directly by the problem, namely, the energy function 
being optimized.[67] 
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In our case, the fitness or energy is calculated from the ligand’s coordinates, which together form 
its phenotype. The genotypic representations of the ligand, and its mutation and cross over 
operators, have already been described. The developmental mapping simply transforms a 
molecule’s genotypic state variables into the corresponding set of atomic coordinates. This 
means that the developmental mapping does not need to be inverted. Nonetheless, this molecular 
variation of the genetic algorithm still qualifies as Lamarckian, because any ‘‘environmental 
adaptations’’ of the ligand acquired during the local search will be inherited by its offspring. At 
each generation, it is possible to let a user defined fraction of the population undergo such a local 
search. We have found improved efficiency of docking with local search frequencies.[68] 
5.2.1.2 Autodock procedure.[69] 
Docking studies of compounds S5a-o; s6a-f were performed using one cyclooxygenase-2 protein 
(PDB ID: 1CX2) obtained from the RCSB protein data bank,http://www.rcsb.org/pdb. 
Experiments were performed using the program Autodock module version 4.0. 
AutoDock includes 3 steps:  
1. Preparation of receptor & ligand files.  
2. Calculation of affinity maps by using a 3D grid around the receptor & ligand.  
3. Defining the docking parameters and running the docking simulation.  
The preparation step starts with pdb files of receptor (R.pdb) and ligand (L.pdb), which are 
added hydrogens and then saved as RH.pdb & LH.pdb. The calculation of affinity maps in the 
"Grid" section requires the above pdb files to be assigned charges & atom types, and also that the 
nonpolar hydrogens are merged. This is done automatically by ADT, and the resulting files need 
to be saved as RH.pdbqt & LH.pdbqt, which is the only format AutoGrid &AutoDock can work 
with. Calculation of affinity maps is done by Auto Grid, and then docking can be done by 
AutoDock. The newest docking algorithm is LGA (Lamarckian Genetic Algorithm).  
 
Preparing and Running a Docking  
1. Preparing the protein  
 Opening file: [Right-click "PMV molecules"] → [choose file].  
 Color by atom: [Click under "Atom"].  
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 Eliminate water: Select → Select from string → [write HOH in "Residue" line 
and in the "Atom" line] → Add → Dismiss → Edit → Delete → Delete Atom 
Set.  
 Find missing atom and repairing them: File → Load module → [Pmv; repair 
Commands] → Edit → Misc. → Check for missing atoms → Edit → Misc. → 
Repair missing atoms.  
 Add hydrogen’s: Edit → Hydrogen’s → Add → [choose "All hydrogen’s", "no 
bond order", and "Yes" to renumbering].  
 Hide protein: [Click on the gray under "show Molecules"]. (Note: if you are 
planning rigid docking (i.e. no flexible parts in the protein), save the protein as 
RH.pdb for now)  
2. Preparing the ligand  
 Make sure the ligand has all hydrogens added before working with ADT. 
 Toggle the "AutoDock Tools" button.  
 Opening file: Ligand → Input → Open → All Files → [choose file] → Open. 
(ADT now automatically computes Gasteiger charges, merges nonpolar 
hydrogens, and assigns Autodock Type to each atom.)  
 Define torsions:  
* Ligand → Torsion Tree → Detect Root (this is the rigid part of the ligand)  
* Ligand → Torsion Tree → Choose Torsions → [either choose from the viewer 
specific bonds, or use the widget to make certain bond types active (rotatable) or 
inactive (non-rotatable). Amide bonds should NOT be active (colored pink)] → 
done.  
* Ligand → Torsion Tree → Set Number of Torsions → [choose the number of 
rotatable bonds that move the 'fewest' or 'most' atoms].  
Save ligand file:  
* Ligand → Output → Save as PDBQT → [save with L.pdbqt]. 
Hide the ligand, as explained in (A5) for the protein.  
3. Preparing the flexible residue file (Note: if you are planning rigid docking, ignore this section 
and do the following: Grid → Macromolecule → Open → [choose RH.pdb]. AutoDock will 
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automatically add charges and merge hydrogens. Save the object as RH.pdbqt and move to next 
section.)  
 Flexible residues → Input → Choose molecule → [choose the original protein 
R.pdb] → Yes to merge nonpolar hydrogens (AutoDock assigns charges + atom 
types to R.pdb, and merges nonpolar hydrogens).  
 Select the residues to be flexible: Select → Select from string → ARG8 → Add 
→ Dismiss.  
 Define the rotatable bonds: Flexible residues → Choose torsions in currently 
selected residues → [click on rotatable bonds to inactivate them, or vice versa].  
 Save the flexible residues: Flexible residues → Output → Save flexible PDBQT 
→ [save as R_flex.pdbqt].   
 Save the rigid residues: Flexible residues → Output → Save rigid PDBQT → 
[save as R_rigid.pdbqt].  
 Delete this version of protein: Edit → Delete → Delete Molecule → [choose 
protein (R)] → Delete → Dismiss.  
4. Running AutoGrid calculation the purpose of this section is to define the search grid and 
produce grid maps used later by Autodock.  
 Open the rigid protein: Grid → Macromolecule → Open → [choose the rigid 
protein] → Yes to preserving the existing charges. (Note: if you are doing rigid 
docking, choose RH.pdbqt) 
 Prepare grid parameter file: Grid → Set Map Types → Choose Ligand → [choose 
the ligand already opened] → Accept. 
 Set grid properties: Grid → Grid Box → [Set the grid dimensions, spacing, and 
center] → File → Close Saving Current. 
 Save the grid settings as GPf file: Grid → Output → Save GPF → [save as 
R.gpf]. 
 Running: Run → Run AutoGrid → [make sure the program name has the right 
path, and that it is where the input files are] → Launch → [in the command 
prompt prompt, type "tail –f hsg1.glg" to follow the process] (Note: the AutoGrid 
calculation can be started directly from the command prompt by typing "autogrid4 
–p hsg1.gpf –l hsg1.glg "). 
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5. Preparing the docking parameter file (.dpf)  
 Specifying the rigid molecule: Docking → Macromolecule → Set Rigid Filename 
→ [choose R_rigid.pdbqt]. (or RH.pdbqt for rigid docking)  
 Specifying the ligand: Docking → Ligand → Choose → [choose L.pdbqt] → 
[here you can set the initial location of the ligand] → Accept. 
 Specifying the flexible residues: Docking → Macromolecule → Set flexible 
Residues Filename → [choose R_flex.pdbqt]. 
 Setting the parameters for the chosen docking method: Docking → Search 
Parameters → Genetic Algorithm → [for 1st time, use the short number of 
evaluations (50,000), and for other runs choose the medium or long] → Accept. 5. 
Setting docking parameters: Docking → Docking Parameters → [choose the 
defaults].  
 Specifying the name of the ligand dpf file to be formed, containing the docking 
instructions: Docking → Output → Lamarckian GA → [type L.dpf].  
 Confirming the details of docking: Docking → Edit DPF → [make sure the right 
ligand pdbqt file name appears after the word "move", and that the right number 
of active torsions is specified].  
6. Running AutoDock  
 Make sure the AutoDock executable is in the same directory as the 
macromolecule, ligand, GPF, DPF and flex files (in case of flexible docking).  
 Running: Run → Run AutoDock... → Launch.  
7. When RH and LH already exist  
 Protein: Grid → Macromolecule → choose RH.pdb → (charges & atom types assigned, 
nonpolar hydrogen merged) → File → save → write PDBQT → save as RH.pdbqt  
Ligand: Ligand → Input → Open → All Files → choose LH.pdb → (charges & atom 
types assigned, nonpolar hydrogen merged) → save as LH.pdbqt  
 Set the rest of the grid parameters & calculate map  
 Setting Docking parameters: Docking → Macromolecule → Set Rigid Filename → 
choose either RH.pdbqt or RH_rigid.pdbqt → Docking → Ligand → Choose → choose 
LH.pdbqt → set the rest of the docking parameters.  
 Running docking simulation.  
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8. Viewing Docking Results  
A. Reading the docking log file (.dlg)  
 Analyze → Dockings → Open → [choose L.dlg].  
 Analyze → Conformations → Load → [double-click on each conformation to 
view it on screen].  
B.Visualizing docked conformations  
 Analyze → Conformations → Play... (Note: & allows changing the ligand's color)  
 
 
5.2.2 Experimental protocol 
The experimental work conducted the following sub headings. 
5.2.2.1 Scheme: 
Scheme I :- 
Step (i): Synthesis of various substituted 4-phenylthiazol-2-amines(Compounds S8a-e) 
Step(ii): Synthesis of various substituted4-phenyloxazol-2-amines(Compounds S9a-b)  
Scheme II  :- 
Step (i): Synthesis of ethyl 2-oxo-2H-chromene-3-carboxylate(Compound S2). 
Step (ii):Synthesis of 2-oxo-2H-chromene-3-carboxylic acid(Compound S3). 
Step (iii): Synthesis of various amide derivatives of 2-oxo-2H-chromene-3-carboxylic acid 
(Compound S4a-c). 
Step (iv): Synthesis a series of 1-heterocyclic substituted quinoline-2-one derivatives 
(Compounds S5a-o; S6a-f). 
5.2.2.2 Physicochemical studies of synthesized compounds. 
5.2.2.3Spectral analysisof synthesized compounds. 
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5.2.2.1 SCHEME -I: 
 
 
 
Reagents and condition: 
     (i)Thiourea, S7a-e, I2, hot H2O, ether, NH3;  
(ii) Urea, S7a-b, I2, hot H2O, ether, NH3. 
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Scheme-II 
 
 
Reagents and Conditions:(i)Salicylaldehyde, Diethyl malonate, pyridine, 0-5°C, stirring 20 min; 
(ii)Compound (S2),0.1N NaOH stirring for 45min, 1N HCl;(iii)Compound (S3),DMF,DCC 
Microwave irradiation at 300W for 2-3min; (iv)Compounds(S4a-c), Compounds (S8a-e;S9a-b)in 
glacial acetic acid,Microwaveirradiation at 450W for 10-12 min. 
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Table 5.1 Compounds (S5a-o) 
N O
R
N S
R1
O
 
Cpd code R R1 
S5a 
NH2N
 
H 
S5b 
NH2N
 
-F 
S5c 
NH2N
 
-CH3 
S5d 
NH2N
 
-OCH3 
S5e 
NH2N
 
-NO2 
S5f 
N N CH3
 
-H 
S5g 
N N CH3
 
-F 
S5h 
N N CH3
 
-CH3 
S5i 
N N CH3
 
-OCH3 
S5j 
N N CH3
 
-NO2 
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Cpd code R R1 
S5k 
N N C6H5
 
-H 
S5l 
N N C6H5
 
-F 
S5m 
N N C6H5
 
-CH3 
S5n 
N N C6H5
 
-OCH3 
S5o 
N N C6H5
 
-NO2 
Table 5.2 Compounds (S6a-e) 
N O
R
N O
R1
O
 
Cpd code R R1 
S6a 
NH2N
 
-H 
S6b 
NH2N
 
-F 
S6c 
N N CH3
 
-H 
S6d 
N N CH3
 
-F 
S6e 
N N C6H5
 
-H 
S6f 
N N C6H5
 
-F 
 
 
 
 
 
 
5.2.2.2 PROCEDURE: 
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Scheme 1 :-[70] 
Step (i): Synthesis of various 4-phenylthiazol-2-amines (Compounds S8a-e;)  
A mixture of various substituted acetophenone (0.1 mole), thiourea(0.2 mole) and iodine (0.1 
mole) was heated on a steam bath for 4-5 h. The hydroiodide, thus separated, was filtered, 
afforded pale yellow powder, washed with ether and dried. Resulting product was dissolved in 
hot water, filtered while hot and the clear solution neutralized with a strong solution of ammonia. 
The solid separated was filtered,dried and recrystallized. 
 
Step (ii) Synthesis of various 4-phenyloxazol-2-amines (Compounds S9a-b). 
A mixture of various substituted acetophenone (0.1 mole), urea (0.2 mole) and iodine (0.1 mole) 
was heated on a steam bath for 4-5 h. The hydroiodide, thus separated, was filtered, afforded pale 
yellow powder, washed with ether and dried. Resulting product was dissolved in hot water, 
filtered while hot and the clear solution neutralized with a strong solution of ammonia. The solid 
separated was filtered,dried and recrystallized. 
 
Scheme II:- 
Step (i) :Synthesis of ethyl 2-oxo-2H-chromene-3carboxylate (Compound S2): [71] 
          To a cold mixture of salicylaldehyde (0.2Mole) and diethyl malonate (0.2Mole), 2 mL of 
piperidine was added by rapid stirring. After 20 min the yellow solid separated was filtered off 
subsequently washed with ethanol and recrystallized from water: ethanol (2:8). 
 
Step(ii) :Synthesis of 2-oxo-2H-chromene-3-carboxylic acid (Compound S3). 
Compound(S2)was dissolved in 0.1N NaOH and stirred in a magnetic stirrer for about 45 min. 
The resulting solution was filtered, filtrate collected, acidified with 1N HCl to give 
compound(S3). 
 
Step (iii): Synthesis of various amide derivatives of 2-oxo-2H-chromene-3-carboxylic acid 
(Compound S4a-c).[72] 
A mixture of 2-oxo-2H-chromene-3-carboxylic acid(compound S3) (1mole) and N,N’ di-
cyclohexylcarbo-di-imide (DCC) (2mole) in 20mL of dichloromethane and was stirred for 10min 
at 0-5ºC. To this mixture the respective secondary amines were added and irradiated in a 
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microwave at 300W for 2-3min. The solid urea separated was filtered off and the organic layer 
was washed with ice cold water to yield the desired product. 
 
Step (iv) : Synthesis of series of quinoline-2-one derivatives from  various amide substituted 
2-oxo-2H-chromene-3-carboxylic acid by coupling with synthesised 4-phenylthiazol-2-
amines   (Compounds S5a-o;S5a-e).[73] 
Equivalent mole(0.1mole) of compounds (S8a-e; S9a-b) andcompounds (S4a-c)in presence of 
glacial acetic acid were irradiated with microwave at 450 watts for 10 -12 min. The excess 
solvent was distilled off under reduced pressure and poured into crushed ice to get the solid. The 
product so obtained was filtered under suction and dried at room temperature. It was purified by 
recrystallisation from absolute ethanol. 
 
5.2.3 Physicochemical studiesof synthesized  compounds. 
5.2.3.1 Melting point analysis: 
The melting point of the compounds were determined in one end fused capillary tubes on 
a THERMONIC MODEL-C-LMP-1, Campbell melting point apparatus was used to evaluated 
the purity of the synthesized compounds and are uncorrected. 
5.2.3.2 Clog P 
Molecular formula, molecular weight and clog P were determined by using the software 
Chem Draw 0.8 April 2003. 
5.2.3.3 Thin layer chromatography: 
 TLC is an important analytical tool in the separation, identification and estimation of 
different classes of natural and synthetic compounds. Thin layer chromatography is a method of 
analysis in which the stationary phase is a finely divided solid, spreaded as a thin layer on a rigid 
supporting plate and the mobile phase. 
Principle: 
The principle involved in this technique is “ADSORPTION”, which involves the separation and 
identification of the compound, by a differential migration of the compound between two phases. 
a) Stationary phase: Finely divided solid, is spread as a thin layer on a rigid supporting 
plate. 
b) Mobile phase: It is a liquid allowed to migrate across the surface of the plate. 
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Need for TLC in identification of synthesised compounds: 
 To establish the purity and authenticity of starting materials and reagents. 
 To monitor reactions, particularly in the case of new reactions. 
 Assessment of purity of a crude reaction product. 
 The optimization of experimental conditions to achieve the highest possible 
yield of product. 
Procedure: 
Stationary phase   : Silica gel-G (Merck-E). 
Mobile phase        : Ethyl aceto acetate : Hexane (1:1). 
Detecting agent     : Iodine vapour. 
Method                 : Ascending TLC 
Supporting plate    : Glass (5x 20 cms) 
Preparation of plate: 
Uniform slurry of silica gel G was prepared by addition of distilled water, poured into the 
spreading trough and drawn across the glass plate of size 5 x 20 cm, depositing a uniform layer 
of 0.25 mm thickness. The plates were dried and then activated by heating at 110⁰C for 1h and 
stored over a dessicator until used. 
Selection of mobile phase: 
Evaluation of various mobile phase was tried, alone or in combination in which ethyl acetate : 
Hexane (1:1) was found to be suited. 
Sample application and development: 
Sample was applied as a small spot at about 2cm from the base of plate. For ascending 
development, the plate was placed in the TLC chamber which was saturated previously with 
mobile phase .The solvent was allowed to move until it travelled a distance of about 15cm from 
the point of application. The plate was then removed and the solvent front was marked and it was 
allowed to evaporate. 
Detection:   
For detection of solute spots, the plates were placed in a chamber containing iodine crystals 
which sublimes to produce an atmosphere saturated by the vapours. The solute spot was visible 
as brown spots. 
5.2.4 Spectral studies: 
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 The structures of the compounds were confirmed by Infrared Spectroscopy, Proton 
Nuclear Magnetic Resonance and Mass Spectroscopy analysis. 
5.2.4.1 Ultraviolet spectral analysis (UV)): 
Molecular absorption in the ultraviolet and visible region of spectrum is dependent onthe 
electronic structure of molecule. Characteristic group with diverse electronic environment 
absorbs at selective wavelength, and helps in recognising characteristic groups in a molecule of 
widely varying complexity. 
             UV spectra are recorded on SHIMADZU 1700A, spectrophotometer. Spectral grade 
ethanol was used as solvent.  
5.2.4.2 Infrared spectral analysis (IR): 
 The range of electromagnetic radiation between 0.8 and 500µm is referred as infrared radiation, 
which is represented with percent transmittance as the ordinate and the wave number(cm-1) as the 
abscissa. 
Applications: 
 Determination of identity of a compound by means of spectral comparison with that of 
authentic sample. 
 Verification of the presence of functional groups in unknown molecules. 
Procedure: 
Pellet technique is used .Solid samples (0.5-1mg) were intimately mixed with appropriate solid 
sample of dry powdered potassium bromide. The mixture was pressed between a punch and disc 
under pressure of 1,00000 -15,000 psi to form a transparent disc. The IR spectral study was done 
on JASCO FTIR 4100. 
5.2.4.3 Nuclear Magnetic Resonance spectral analysis (1H NMR): 
The NMR spectra of the synthesized compounds were recorded by Bruker Fourier, Transform-
NMR using TMS (Tetramethylsilane) as internal standard. The PMR (Proton Magnetic 
Resonance) spectroscopic values were measured in δ ppm in DMSO-d6. 
 
5.2.4.4 Mass Spectral analysis: 
 The mass spectra of newly synthesized compounds were recorded on JEOL GCMATE 
instrument. The mass of the compounds are expressed in m/z values. 
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EXPERIMENTAL WORK (PHARMACOLOGICAL ACTIVITY) 
5.2.5. In vitro antioxidant activity 
5.2.5.1 DPPH radical scavenging assay. [74][75] 
Reagents 
 0.3mM Diphenyl-2-picrylhydrazyl (DPPH). 
 Ethanol. 
 Ascorbic acid (1mg/mL). 
Principle 
The molecule of 1,1-diphenyl-2-picrylhydrazyl (α, α-diphenyl-β-picrylhydrazyl; DPPH) is 
characterized as a stable free radical by virtue of the delocalization of the spare electron over the 
molecule as a whole, so that the molecules do not dimerise, as would be the case with most other 
free radicals. The delocalization also gives rise to the deep violet colour, characterized by an 
absorption band in ethanol/methanol solution centred at about 520 nm.When a solution of DPPH 
is mixed with a substance that can donate a hydrogen atom,this gives rise to the reduced form 
with the loss of violet colour; although there would beexpected to be a residual pale yellow 
colour from the picryl group still present. Representing theDPPH radical by Z• and the donor 
molecule byAH, the primary reaction  
Z•+ AH            ZH + A• 
Procedure 
The antioxidant activity of the compound was measured in terms of hydrogen donating or radical 
scavenging ability, using the DPPH method. 0.3mM solution of DPPH in ethanol was prepared 
and 1mL of this solution was added to 500 µL of various concentrations of sample (50,100, 200, 
300, 400 and 500 µg/mL)and thereference compound.The mixture was shaken vigorously and left 
to stand in thedark at room temperature for 30 min. Then the absorbance was measured at 517 nm 
against a blank. Reference compounds used were ascorbic acid and quercetin. A control reaction 
was carried out without the test sample. The percentage of inhibition was calculated by 
comparing theabsorbance valuesof the control and test samples. Antiradical activity was 
expressed as percentage inhibition and calculated using the following equation: 
Percentage inhibition (I %) = (Abs control- Abs sample /Abs control) X 100 
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Where ‘Abscontrol’ was the absorbance of the control reaction and ‘Atest’ was the absorbance in the 
presence of the sample/ standard. The antioxidant activity of the compounds was expressed as 
IC50. (IC50 - concentration required to obtain a 50% radical scavenging activity). 
 
5.2.5.2 ABTS*+ Radical Cation Assay.[76][77] 
Reagents 
 7 mM 2,2,- azinobis (3-ethylbenzoline-6-sulfonic acid) ABTS salt 
 2.45 mM ammonium per sulphate. 
 Ascorbic acid (1mg/mL). 
Principle 
ABTS decolorization assay is an inhibition method. The peroxidase substrate 2, 2’-azinobis (3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS), forms a relatively stable radical (ABTS+) upon 
one electron oxidation. The formal reduction potential for ABTS is high enough for it to act as 
anelectron donor for the reduction of reactive oxygen species such as molecular oxygen and 
hydrogen peroxide, particularly at extreme pH values encountered in biological catalysis. Under 
this condition, the sulphonate groups are fully deprotonated and the mediator exists as a 
“dianion”.  
                         ABTS   +  e-   ABTS-. 
                         ABTS-+  e-   ABTS2-. 
Procedure 
ABTS radical cation (ABTS*+) was produced by reacting equal volumes of 7mM ABTS salt and 
2.45 mM ammonium per sulfate and the mixture was allowed to stand in the dark for 16 h at 
room temperature. The resultant solution was diluted with ethanol until an absorbance of 0.70 ± 
0.02 at 734 nm was obtained. Varying concentrations(0.5, 1, 2.5, 5, 10 µg/mL) of the samples 
were allowed to react with 900 µl of ABTS*+ solution. After 20 min the absorbance reading 
were recorded at 734 nm and compared with the control ABTS solution. A control reaction was 
carried out without the sample. The ABTS*+ scavenging capacity of the compound was 
compared with that of ascorbic acid and quercetin. All the tests were performed in triplicate in 
order to get the mean values. The percentage inhibition of ABTS+ by the sample was calculated 
according to the formula: 
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Abs control - Abs sample 
 Percentage inhibition (I %)   =                                         X 100 
                                                      Abs control 
Where ‘Abscontrol’ was the absorbance of the control reaction and ‘Atest’ was the absorbance in the 
presence of the sample/ standard. The antioxidant activity of the compound was expressed as 
IC50. (IC50 - concentration required to obtain a 50% radical scavenging activity). 
 
5.2.6. Toxicological evaluation. [78] 
Acute toxicity study 
Guideline: OECD-423 
Method: Acute Toxic Class 
Principle:  
This method allows for the determination of LD50 value only when two doses result in mortality 
higher than 0% and lower than 100%.The principle of the test, based on a stepwise procedure 
with the use of a minimum number of animals, each step using three animals of a single sex 
(normally females) from which sufficient information is obtained regarding the acute toxicity of 
test substance. Absence or presence of compound- related mortality of the animals dosed at 
One step will determine the next step, i.e; 
 no further testing is needed, 
 dosing of three additional animals, with the same dose 
 dosing of three additional animals at the next higher or the next lower dose level. 
Procedure: 
Selection of animals: 
 Species : Rats 
 Strain   : Albino Wistar 
 Age  : 8-12 weeks 
 Weight : 20-25 g 
Conditions to be maintained:  
 Humidity: 30-70% 
 Temperature: 22 ± 30C 
 Lighting:12hr dark  and 12 hr light cycle 
QUINOLIN-2-ONE ANALOGS: IN SILICO DESIGN, SYNTHESIS, IN VITRO  ANTIOXIDANT, IN VIVO ANTI-
INFLAMMATORY, ANALGESIC AND ULCEROGENIC POTENTIAL STUDIES 
 
Reg 261425820 
 
64 
 Feed : Standard pellet diet 
Grouping of animals: 
The animals are randomLy selected, marked to permit individual identification, grouped (3 
animals per group and kept in their cages for at least 5 days prior to dosing to allow for 
acclimatisation to the laboratory conditions. 
 
Dose  : 5, 50,300,2000mg/kg 
 
Preparation of dose: 
The drug substance is suspended in the suitable solvent i.e. 1% CMC (whose toxicity 
characteristic is evaluated and proved to be safe).Doses must be prepared shortly prior to 
administration. 
 
Administration of dose: 
The animals should be kept fasting (food is with held but free access to water) 4h prior to the 
treatment. The test substance is administered in a single dose by oral route. The dose is gradually 
increased with each step starting with 5, 50.300, 2000mg/kg. After the substance has been 
administered, food may be withheld for further 1-2 h in rats. 
 
Observation 
Animals were observed individually after dosing at least once during the first 30 min, 
periodically during the first 24 h, with special attention given during the first 4 h and daily 
thereafter, for a total of 14 days. Observations included any change in skin and fur, eyes and 
mucous membranes, respiratory, circulatory, autonomic and central nervous system, 
somatomotor activity and behaviour pattern. Attention was directed to observations of mortality, 
tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. If mortality is observed in 
2/3 or 3/3 animals, then the dose administered is assigned as toxic dose (LD50), mortality 
observed in one animal out of three animals, then the same dose was repeated again to confirm 
the toxic effect. If the mortality is not observed in the given dose, then the treatment proceeds 
with the next dose to another group making the observations as mentioned. 
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5.2.7 Pharmacological evaluation[79] 
5.2.7.1 Screening of anti-inflammatory activity 
Experimental methods: 
Anti-inflammatory activity was assessed by carrageenan induced paw oedema method and cotton 
pellet induced granuloma method. 
 
5.2.7.1.1 Carrageenan induced paw edema in rats.[80][81] 
Experimental design: 
Wistar albino rats weighed around 150-250g were used for the study. 24 rats were divided into 6 
groups of 6 rats each for various treatments. 
Group I :   Served as negative control which received carrageenan 1%w/v (0.1mL, S.C) 
Group II :   Served as positive control which received Diclofenac (20 mg/kg, i.p) 
Group III :   Served as test group which received test compound (S5i) (62.5 mg/kg p.o). 
Group IV :  Served as test group which received test compound (S5i) (125mg/kg p.o). 
Group V :   Served as test group which received test compound (S5m) (62.5mg/kg p.o). 
Group VI :   Served as test group which received test compound (S5m) (125mg/kg p.o ). 
Procedure 
          Anti-inflammatory activity was determined according to the method of Winter et al. The 
rats were divided into groups of 6 animals each. The different groups were treated withcompound 
S5i and S5m ( 62.5 and 125 mg/kg p.o) and Diclofenac (20 mg/kg i.p). After 30 min, the rats 
were challenged with subcutaneous injection of 0.1 mL of 1% w/v solution of carrageenan into 
the sub plantar region of left paw. The paw was marked with ink at the level of lateral malleolus 
and immersed in mercury up to the mark. The paw volume was measured at 0,1,2,3,4 and 5h after 
carrageenan injection using a volume displacement method using Plethysmometer by immersing 
the paw in mercury cell. The inflammation in paw volume is calculated as percentage compared 
with the basal volume. The difference of average values between treated animals and control 
group is calculated for each time interval and evaluated statistically. The percentage inhibition of 
paw edema was calculated by using the following formula;  
Percentage of edema inhibition = (Vc -Vt/Vc) × 100 
Vc- Volume of paw edema in control group. 
Vt- Volume of paw edema in treated groups. 
QUINOLIN-2-ONE ANALOGS: IN SILICO DESIGN, SYNTHESIS, IN VITRO  ANTIOXIDANT, IN VIVO ANTI-
INFLAMMATORY, ANALGESIC AND ULCEROGENIC POTENTIAL STUDIES 
 
Reg 261425820 
 
66 
5.2.7.1.2 Cotton pellet induced granuloma method.[82][83] 
Experimental design: 
Wistar albino rats weighed around 150-250g were used for the study. 24 rats were divided into 4 
groups of 6 rats each for various treatments. 
Group I :   Served as negative control which received 1% CMC (0.1mL/10g p.o) 
Group II :   Served as positive control which received Diclofenac (20 mg/kg, i.p) 
Group III :   Served as test group which received test compound (S5i) (62.5 mg/kg p.o). 
Group IV :   Served as test group which received test compound (S5i) (125 mg/kg p.o). 
Group V :   Served as test group which received test compound (S5m) (62.5 mg/kg p.o). 
Group VI :   Served as test group which received test compound (S5m) (125 mg/kg p.o ). 
Procedure 
            The method of Winter and Porter was used to study chronic inflammation. Animals were 
divided into four groups of six each, anaesthetized with ether .The axillary skin was shaved and 
disinfected with 70% ethanol. An incision wasmade and by a blunt forceps subcutaneous tunnels 
were formed and a sterilized cotton pellet (20±5mg) was placed in axilla. The test compound, 
diclofenac and vehicle were administered for 7 consecutive days starting from day of cotton 
implantation. At 8th day rats were anaesthetized again and cotton were removed surgically and 
freed from extraneous tissue. The pellets were weighed immediately for wet weight. Then pellets 
were dried in an incubator at 60°C until weight become constant. The net dry weight of each 
cotton pellet was determined (after subtracting the initial weight of the cotton pellet). The mean 
weights of the cotton pellet of the control and treatment groups were calculated. The percentage 
of anti-inflammatory activity was calculated by inhibition of increase in the weight of the cotton 
pellet was estimated.The percentage inhibition increase in the weight of the cotton pellets was 
calculated by:  
 
Percentage inhibition = Wc – Wt x 100 
                             Wc 
Where, Wc = Pellet weight of the control group  
Wt = Pellet weight of the drug treated group 
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5.2.7.2 Screening of analgesic activity 
Experimental methods 
Analgesic activity was assessed by hot plate and acetic acid induced writhing method. 
5.2.7.2.1 Hot plate method. [84][85] 
Experimental design: 
Swiss Albino mice weighing around 20-25g were used for this study. They were divided into 4 
groups of 6 mice each. 
Group I :  Served as positive control which received morphine (5mg/kg, i.p). 
Group II :   Served as test group which received test compound (S5i)(62.5 mg/kg p.o). 
Group III :  Served as test group which received test compound (S5i) (125 mg/kg p.o). 
Group IV :   Served as test group which received test compound (S5m)(62.5 mg/kg p.o). 
Group V :   Served as test group which received test compound (S5m) (125 mg/kg p.o ). 
Procedure 
     Evaluation of analgesic activity of test compound was carried out using hot plate method. 
Mice were screened by placing them on a hot plate (Medicraft analgesiometer Mark III, 
Medicraft electro medicals (P) Ltd; Lucknow, India) maintained at 55± 10C and the reaction time  
in seconds for hind paw licking or jumping were recorded. Only mice which reacted within 15 
sec and which did not show large variation when tested on four separated occasions, each 15 min 
apart, were used in this study. Morphine (5mg/kg, s.c) was used as standard. 
           After administration of test drugs and standard drug, the animals are placed on the hot 
plate and the time until either licking or jumping occurs is recorded by a stop-watch. The latency 
was recorded before and after 0.15,30,45 and 90min. The latency period for hind paw licking or 
jumping on the heated plate of analgesiometer was taken as reaction time. The prolongation of 
the latency times comparing the values before and after administration of the test compounds was 
used for statistical comparison. 
 
5.2.7.2.2 Acetic acid induced writhing method 
Experimental design: 
Swiss Albino mice weighing around 20-25g were used for this study. They were divided into 4 
groups of 6 mice each. 
Group I :   Served as negative control which received acetic acid (0.1mL/10g  i.p) 
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Group II :   Served as positive control which received diclofenac (20 mg/kg, i.p) 
Group III :   Served as test group which received test compound (S5i)(62.5 mg/kg p.o). 
Group IV :  Served as test group which received test compound (S5i) (125 mg/kg p.o). 
Group V :   Served as test group which received test compound (S5m)(62.5 mg/kg p.o). 
Group VI :   Served as test group which received test compound (S5m) (125 mg/kg p.o ). 
Procedure: 
Animals were divided into five groups of six each. The control group received 0.1mL 1% CMC 
solution p.o. The test group was treated with 62.5 and 125 mg/k.p.o of compounds S5i and S5m. 
The standard group received diclofenac at a dose of 20mg/kg/i.p. After 30min  of drug 
administration 1% acetic acid was given to each mouse at the dose of 0.1mL/10g body weight i.p. 
Number of writhing was counted for 15 min. The percentage inhibition of writhing offered by the 
test samples to the animals was calculated and compared with the control. 
For all the tests, statistical analysis was performed using one way ANOVA followed by  Dunnet 
test in graphpad prism 5 software. 
 
5.2.7.3 Ulcerogenic effect[86] 
Experimental design 
Wistar albino rats weighed around 150-250g were used for the study. Rats were divided into 6 
groups of 6 rats each for various treatments. 
Group I :   Served as negative control which received CMC(0.1mL/10g p.o) 
Group II :   Served as positive control which received indomethacin (20 mg/kg, p.o) 
Group III :   Served as test group which received test compound (S5i)(125 mg/kg p.o). 
Group IV :  Served as test group which received test compound (S5i) (62.5mg/kg p.o). 
Group V :   Served as test group which received test compound (S5m) (62.5 mg/kg p.o). 
Group VI :   Served as test group which received test compound (S5m) (125 mg/kg p.o ) 
Procedure 
The animals  were starved overnight (water ad libitum) prior to drug administration. Doses which 
showed action in the anti-inflammatory tests in rats were chosen(62.5mg/kg and 125 mg/kg). The 
animals are sacrificed 5h post drug administration. Stomachs were removed and placed on saline-
soaked filter paper until inspection. A longitudinal incision along the greater curvature was made 
with fine scissors. The stomach was inverted over the index finger and the presence or absence of 
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gastric irritation was determined. The presence of a single or of multiple lesions (erosion, ulcer or 
perforation) was considered to be positive. The number of ulcers and the occurrence of 
hyperaemia were noted. 
5.2.8Anti-bacterial activity[87] 
5.2.8.1 Zone of inhibition 
Preparation of inoculums 
The inoculums for the experiment were prepared in fresh Nutrient broth from the preserved slant 
culture. The turbidity of the culture can be adjusted by the addition of broth or sterile saline  (if it 
is excessive) or by further incubation to get the required turbidity, And the newly prepared  
inoculums were standardized by adjusting the turbidity of the culture to that of McFarland 
standards. 
Preparation of sterile swabs 
Cotton wool swab on wooden applicator or plastics were prepared and sterilized by autoclaving 
or by dry heat (only for the wooden swabs). It was sterilized by packing the swabs in culture 
tubes. 
Sterilization of forceps 
Forceps was sterilized by dipping in alcohol and burning off the alcohol. 
Procedure 
The standardized inoculums were inoculated in the sterilized plates prepared earlier (aseptically) 
by dipping a sterile loop into the inoculums The excess inoculum was removed by passing and 
rotating the swab firmLy against the side of the culture tube above the level of the liquid. Finally 
the swab was all over the surface of the medium 3 times rotating the plate through an angle of 
60º after each application, further moving the swab round the edges of the plate. The inoculated 
plates were kept closed and were allowed to dry at room temperature. The sterile discs (Himedia 
lab.Pvt.Ltd.,Mumbai) soaked in the test solutions were placed over the solidified media by using 
a sterile forceps. Ciprofloxacin (10µg) discs were used as standard. The plates were incubated at 
37ºC for 24 h and zone of inhibition of each sample was measured and noted 
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Table 5.3Bacterial strain used for the study with NCIM 
 
5.2.8.2 Minimum inhibitory concentration 
The minimum inhibitory concentration (MIC) is the lowest concentration of a chemical that 
prevents the visible growth of the organism.ie, the lowest concentration at which it has 
bacteriostatic activity. 
 
Preparation of test drug: 
The selected test drugs were prepared in DMSO at a concentration 100µg/mL 
 
Preparation of inoculum: 
Bacillus subtilisand Pseudomonas aeuroginosa were the two strains of organisms selected for the 
study. Overnight culture are grown at 370C Kirby- Bauer procedure and diluted to Muller Hinton 
Broth. This overnight culture was diluted to 10-2. 
Inoculation 
The sterile tubes were labelled 1-8 and 8th tube was taken as control.1mL of Muller Hinton Broth 
was transferred to all tubes. 1mL of drug solution was added to 1st tube and mixed well.From the 
1st tube 1mL of solution was transferred to the 2nd tube and was repeated up to 7th tube. From the 
final 2 mL volume of 7th tube 1mL of solution was pipette out.0.01mL of culture was added to all 
the test tubes and all the tubes were incubated at 370C for 18-24hrs.After incubation the turbidity 
was observed visually. The highest dilution without growth is the minimal inhibitory 
concentration. 
 
 
 
Sl no. Organism Strain NCIM 
1  
Gram +ve bacteria 
Bacillus subtilis 2063 
2 Staphylococcus aureus 2079 
3  
 
 
Gram –ve bacteria 
Vibrio cholerae 1738 
4 Salmonella Paratyphi 2501 
5 Escherichia coli 2065 
6 Klebsilla Pneumoniae 2707 
7 Pseudomonas Aeuroginosa 2200 
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CHAPTER 6 
RESULT AND DISCUSSION ( DOCKING AND CHEMISTRY) 
Based on the literature review of quinolin-2-ones, compounds were designed and docked with 
COX-2 protein. The general structure for the designed synthesised compounds are as follows. 
N O
R
N S
R1
O
N O
R
N O
R1
O
 
Figure 6.1 General structures of synthesised compounds 
The X-Ray structure of COX-2 (PDB ID 1CX2)[88] in complex with selective inhibitor SC-58 
was obtained from RCSB protein bank and used as template for flexible ligand docking with 
AutoDock 4.2. [89]The enzyme was considered rigid fixed in their crystallographic conformation 
and ligand in the binding was considered fully flexible. Prior to the calculations, a monomer was 
separated and ligand molecule was removed from the template structure and ligand molecule was 
removed from the template structure and hydrogen atoms were added using Molecular operating 
environment (MOE 2013.08)[90].  Atomic partial charges were added with AutoDock Tools[91]. 
Three dimensional grids for calculating the binding energy of the inhibitors were computed 
within a grid in a grid box of 60x60x60 points with a spacing of 0.37A, centred on the co-
crystallised ligand. The inhibitors designed for COX-2 were docked into the active site of the 
enzyme using Lamarckian Genetic Algorithm in AutoDock 4.2. 50 independent docking runs for 
the ligands molecule were run into binding site of COX-2. The other parameters for search 
optimisation and scoring function were set to their default values. Putative compound binding 
modes were selected by visual inspection of high scoring docking poses. 
The crystallographic structure of COX-2 is as shown in the Figure 6.2.Docking stimulations with 
AutoDock 4.2 successfully reproduced the crystallographic pose of COX-2. The ligand S5i in the 
COX-2 binding pocket is stabilised within the binding site through H-bond interactions with 
residues Met 522, Val 523, Gly526 and electronic interactions with residues His90, Thr94, 
Val349, Ser353. The ligand S5m in the COX-2 is stabilised within  the binding site through H-
QUINOLIN-2-ONE ANALOGS: IN SILICO DESIGN, SYNTHESIS, IN VITRO  ANTIOXIDANT, IN VIVO ANTI-
INFLAMMATORY, ANALGESIC AND ULCEROGENIC POTENTIAL STUDIES 
 
Reg 261425820 
 
72 
bond interactions with residues Met 522, Val 523, Ala 527, Ser 353 and electronic interactions 
with amino acid  residues His90, Ser 353, Arg 513, Ala 516,  Gly 52. 
 
Figure 6.2 Crystallographic structure of COX-2 (PDB ID: 1CX2) 
 
Figure 6.3 Binding pocket of  compound S5i and S5m in COX-2 
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Table 6.1 Docking score of the designed ligands 
Compound code and 
structure 
Docking 
score 
Compound code and 
structure 
Docking  
score 
S5a 
N O
O
NH
NN S
 
 
 
-7.21 
S5b 
N O
O
NH
NN S
F  
 
 
-5.49 
S5c 
N O
O
NH
NN S
H3C  
 
 
-5.91 
S5d 
N O
O
NH
NN S
O  
 
 
-7.32 
S5e 
N O
O
NH
NN S
O2N  
 
 
-6.07 
S5f 
N O
O
N
N S
N
CH3
 
- 
 
9.27 
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Table 6.1a Docking scores of designed ligands 
Compound code and  
Structure 
Docking 
score 
Compound code and 
structure 
Docking 
score 
S5g 
N O
O
N
N S
N
CH3
 
 
 
 
-5.40 
S5h 
N O
O
N
N S
N
F  
 
 
 
-6.61 
S5i 
N O
O
N
N S
N
O
 
 
 
 
 
-6.00 
S5j 
N O
O
N
N S
N
O2N  
 
 
 
 
-7.98 
S5k 
N O
O
N
N S
N
 
 
 
 
-1.38 
S5l 
N O
O
N
N S
N
F  
 
 
 
-0.80 
 
 
 
Table 6.1b Docking score of designed ligands 
QUINOLIN-2-ONE ANALOGS: IN SILICO DESIGN, SYNTHESIS, IN VITRO  ANTIOXIDANT, IN VIVO ANTI-
INFLAMMATORY, ANALGESIC AND ULCEROGENIC POTENTIAL STUDIES 
 
Reg 261425820 
 
75 
Compound code and 
structure 
Docking 
score 
Compound code and 
structure 
Docking 
score 
S5m 
N O
O
N
N S
N
H3C  
 
 
 
-4.15 
S5n 
N O
O
N
N S
N
O
 
 
 
 
7.72 
S5o 
N O
O
N
N S
N
O2N  
 
 
 
7.71 
S6a 
N O
O
NH
NN O
 
 
 
 
-6.82 
S6b 
N O
O
NH
NN O
F  
 
 
 
-8.41 
S6c 
N O
O
N
N O
N
 
 
 
 
-8.99 
 
 
 
Table 6.1c Docking score of designed ligands 
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Compound code and 
structure 
Docking 
score 
Compound code and 
structure 
Docking 
score 
S6d 
N O
O
N
N O
F
N
 
 
 
 
-8.49 
S6e 
N O
O
N
N O
N
 
 
 
 
2.35 
S6f 
N O
O
N
N O
N
F  
 
 
 
2.03 
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Taking into consideration that coumarins are well known scaffolds for the anti-oxidant 
analgesic and anti-inflammatory activity, quinolin-2-one analogues which are isosteric to 
coumarins were designed,docked and synthesised according to the mentioned general procedure 
Ester of coumarin derivative (S2) was obtained by cyclization of salicylaldehyde and 
diethyl malonate in presence of pyridine as catalysts. Compound (S2) was hydrolysed to give  
coumarin-3-carboxylic acid,  resulting  compound containing carboxylic was further activated by 
using DCC, then  convert into various 2-amide derivatives  of coumarin by using various amines 
(Compounds S4a-c).  The key intermediate  2-oxo-2H-chromene-3- amide derivatives convert 
into titled compounds (S5a-o, S6a-f) by microwave irradiation with  primary amine like 2-amino 
thiazole (S8a-e) and 2-amino oxazole (S9a-b). 
Physical parameters like percentage yield, molecular weight, molecular formula, melting 
point, Clog-P and Rf value of the synthesized compounds were determined. The titled 
compounds were in moderate yields from 20-70 percentages. Melting point of all newly 
synthesized compounds were determined and are incorrect. The purity for all the synthesized 
compounds was confirmed by a single spot in TLC. Clog P values of all the newly synthesized 
compounds were determined by using Chem draw 12. 
IR spectra of synthesized compounds showed characteristic absorption band around 
3690-3600 cm-1 (NH in hetero aromatic ring), 3000-3100 cm-1 (C-H stretching), 1750-1700 cm-1 
(C=O stretching), 1690-1650 cm-1 (CN stretching), 1570-1500 cm-1 (amide C=O stretching), 
800-600 cm-1 (substituted benzene). 
1H NMR spectra of the synthesized compound (S5i)showed peaks at δ 7.8-6 (m, Ar-H); 
3.8 (d, 3H,-OCH3); 2.3 (s, 3H, CH3 Piperazine);  2.3 (s, 3H, CH3 Piperazine);  1.4 (d, 8H, CH2-
Piperazine) and compound (S5m) showed peaks at δ 8.2-6.5 (m, Ar-H); 3.8 (s, 3H, -CH3 
phenyl);   1.4 (d, 8H, CH2-Piperazine).  Mass spectra showed the desired M + 1 peak. 
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6.1 Physicochemical data 
N O
R
N S
R1
O
 
Compounds S5a-o 
Table 6.2 Physicochemical data of synthesized compounds(S5a-o) 
Cpd 
Code 
R R1 Mol. Formula Mol. 
Wt 
% 
Yield 
M.P 
(° 
C) 
Rf 
Value 
C 
logP 
S5a 4-aminopyridine -H C24H16N4O2S 424.1 70 168 0.7 3.367 
S5b 4-amino pyridine -F C24H15FN4O2S 442.09 62 173 0.75 3.510 
S5c 4-amino pyridine -CH3 C25H18N4O2S 
 
438.12 69 171 0.80 3.86 
S5d 4-amino pyridine -OCH3 C25H18N4O3S 
 
456.51 54 145 0.81 3.38 
S5e 4-amino pyridine -NO2 C24H15N5O4S 
 
469.08 58 141 0.85  
S5f N-methyl 
piperazine 
-H C24H22N4O2S 
 
430.52 44 183 0.95 3.53 
S5g N-methyl 
piperazine 
-F C24H21FN4O2S 
 
448.51 40 170 0.90 3.67 
S5h N-methyl 
piperazine 
-CH3 C25H24N4O2S 
 
444.54 38 186 0.81 4.03 
S5i N-methyl 
piperazine 
-OCH3 C25H24N4O3S 
 
460.54 30 162 0.62 3.42 
 
S5j N-methyl 
piperazine 
-NO2 C24H21N5O4S 
 
475.51 34 169 0.68  
S5k N-phenyl 
piperazine 
-H C29H24N4O2S 
 
492.59 32 183 0.91 5.98 
S5l N-phenyl 
piperazine 
-F C29H23FN4O2S 510.58 31 168 0.76 4.29 
S5m N-phenyl 
piperazine 
-CH3 C30H26N4O2S 506.61 28 172 0.71 4.64 
S5n N-phenyl 
piperazine 
-OCH3 C30H26N4O3S 
 
522.61 24 165 0.69 4.16 
S50 N-phenyl 
piperazine 
-NO2 C29H23N5O4S 
 
537.58 29 159 0.73  
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N O
R
N O
R1
O
 
Compounds 6a-f 
Table 6.2 Physicochemical data of synthesized compounds (S6a-f) 
Cpd 
cod
e 
R R1 Mol. Formula Mol. 
weight 
%yield M.P 
(ºC) 
Rf 
Value 
Clo
gP 
S6a 4-amino pyridine H C24H16N4O3 
 
408.12 24 158 0.90 2.73 
S6b 4-amino pyridine F C24H15FN4O3 
 
426.11 28 159 0.76 2.88 
S6c N-methyl piperazine H C24H22N4O3 
 
414.45 20 144 0.90 2.49 
S6d N-methyl piperazine F C24H21FN4O3 
 
432.44 22 140 0.85 3.04 
S6e N-phenyl piperazine H C29H24N4O3 
 
476.52 29 170 0.87 4.57 
S6f N-phenyl piperazine F C29H23FN4O3 
 
494.51 21 160 0.82 4.73 
 
6.2 Spectral analysis  
6.2.1 Spectral data of compound S5a-o; S6a-f 
Compound S5a λmax:258; IR (cm-1):3473.65 (amide NH stretching); 1718.26 (C=N 
stretching);1562.54(C=O stretching);879.38(-C-S stretching); 
620.96(mono substituted aromatic ring). 
Compound S5b λmax:260; IR (cm-1):3478.95 (amide NHstretching); 1718.75(C=N 
stretching);1627.14(C=O stretching);1563.02(C=Cstretching);899.50(C-S 
stretching); 1040.89(C-F stretching); 769.94 (di-substituted aromatic ring) 
Compound S5c λmax:281; IR (cm-1):3468.83 (amide NHstretching); 2926.45(C-H 
stretching in aliphatic chain); 1718.26(C=N stretching); 1624.14(C=N 
stretching); 1562.06(C=C stretching); 769.94(di-substituted aromatic 
ring); 889.50 (-C-S stretching) 
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Compounds S5d λmax:257; IR (cm-1):3473.65 (amide NHstretching); 3057.1 (C-H 
aromatic stretching); 1717.26 (C=N stretching); 1626.66(C=O stretching); 
1562.54 (C=Cstretching); 1046.19(C-O-C); 894.8(-C-S stretching); 
764.63(di-substituted aromatic ring) 
Compound S5e λmax:207; IR (cm-1):3468.83(-NH2 stretching); 3067.23 (C-H stretching 
in aromatic ring); 1717.78 (C=N stretching); 1626.66 (N=O stretching); 
1562.54 (C=C); 764.637 (di-substituted aromatic ring); 1374.03(C-N 
stretching). 
Compound S5f λmax:262; IR(cm-1):3036.23(aromatic C-H stretching); 2927.87(aliphatic 
C-H stretching); 1627.14 (C=0 stretching); 1573.63 (C=C stretching); 
1311.84 (C-N stretching); 892.39(C-S stretching); 639.76 (mono-
substituted aromatic ring) 
Compound S5g λmax:265; IR (cm-1) : 2928.28 (aliphatic C-H stretching); 1627.63(C=O 
stretching); 1574.59 (C=C stretching); 1312.32(C-N stretching); 
892.39(C-S stretching) 1088.17(C-F stretching); 641.69(di-substituted 
aromatic ring) 
Compound S5h λmax:209; IR (cm-1): 2927.41 (aliphatic C-H); 1627.63 (C=O stretching); 
1574.59 (C=C stretching); 1311.84 (C-N Stretching); 866.6(C-S 
stretching); 641.21 (di-substituted aromatic ring) 
Compound S5i λmax:245; IR (cm-1): 2927.41 (aliphatic C-H stretching); 1627.63(C=0 
stretching); 1574.59 (C=C stretching); 1311.84(C-N stretching); 886.6(C-
S stretching); 641.21(di-substituted aromatic ring). 1H NMR (δ values): 
7.8-6 (m, Ar-H); 3.8 (d, 3H,-OCH3); 2.3 (s, 3H, CH3 Piperazine); 2.3 (s, 
3H, CH3 Piperazine);  1.4 (d, 8H, CH2-Piperazine).   
Compound S5j λmax:266; IR (cm-1) : 1313.77(C-N in tertiary amine); 3026.73( aromatic 
C-H stretching); 2927.80 (aliphatic C-H stretching); 1627.63(N=O 
stretching); 1575.08(C=C stretching); 842.25(C-S stretching); 717.3(di-
substituted aromatic ring). 
Compound S5k λmax:268; IR(cm-1):3044.09 (aromatic C-H stretching); 
2929.34(aliphatic C-H); 1627.6 (C=N stretching); 1576.52 (C=O); 
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1448.76(C=C stretching); 1312.3(C-N stretching); 893.36(C-S stretching); 
642.17(mono-substituted aromatic ring) 
Compound S5l λmax:269; IR(cm-1):3059.75(aromatic C-H stretching); 2928.36 
(aliphatic C-H stretching); 1627.63(C=N); 1576.04(C=O stretching); 
1450.21(C=C stretching); 1312.32 (C-N in tertiary amines); 1089.1(C-F 
stretching) 
Compound S5m λmax: 262; IR (cm-1):3063.3(aromatic C-H stretching); 2927.8(aliphatic 
C-H stretching); 1627.6(C=Nstretching); 1575.56(C=C stretching); 
1311.8(C-N stretching); 892.39(C-S stretching); 642.17(di-substituted 
aromatic ring). 1H NMR (δ values): 8.2-6.5 (m, Ar-H); 3.8 (s, 3H, -CH3 
phenyl);   1.4 (d, 8H, CH2-Piperazine).   
Compound S5n λmax:246; IR(cm-1):3035.4 (aromatic C-H stretching); 
2928.86(aromaticC-H stretching); 1627.6(C=N stretching); 1576.5(C=O 
stretching); 1438.15(C=C stretching); 1312.32 (C-N stretching); 
1048.19(C-O-C); 835.99(C-S stretching); 758.37(di-substituted aromatic 
ring); 641.6(mono-substituted aromatic ring).  
Compound S5o λmax:267; IR (cm-1):2927.89 (aliphatic C-H stretching); 1627.63(C=N 
stretching); 1577.5(C=O stretching); 1312.32(C=N stretching); 
1088.19(C-O-C); 642 (mono substituted aromatic ring) 
Compound S6a λmax:268;IR (cm-1):3469.7(amide NHstretching); 2827.89(aliphatic C-H 
stretching); 1718.75 (C=N stretching); 1627.14(C=O stretching); 
1573.15(C=C stretching); 1088.14(C-O-C); 695.21(mono substituted 
aromatic ring); 1311.84(C-N stretching) 
Compound S6b λmax:263;IR (cm-1):3469.7 (amide NHstretching);3057.1(aromatic C-H 
stretching); 1627.14(C=O stretching); 1508.35(C=C stretching); 
1311.84(C-N stretching); 1088.62(C-O-C); 1042.82(C-F stretching); 
758.8(di-substituted aromatic ring). 
Compound S6c λmax:208; IR (cm-1):3061.44(aromatic C-H stretching); 1627.14(C=O 
stretching); 1572.18(C=C stretching); 2927.89(aliphatic C-H 
stretching);1312.8(C-N stretching); 1098.55(C-O-C); 695.21(di-
substituted aromatic ring) 
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Compound s6d λmax:250; IR (cm-1):3057.1(aromatic C-H stretching); 2927.8 (aliphatic 
C-H stretching); 1720.19(C=N stretching); 1627.14(C=O stretching); 
1574.59(C=C stretching); 1311.84 (C-N stretching); 1088.62(C-O-C); 
1042.82(C-F stretching);757.88(di-substituted aromatic ring). 
Compound S6e λmax:251; IR (cm-1):2927.8 (aliphatic C-H stretching); 1627.14 (C=O 
stretching); 1573.63(C=C stretching);1312.32 (C-Nstretching); 1088.62 
(C-O-C); 642.17(mono-substituted aromatic ring) 
Compound S6f λmax:238; IR (cm-1):3070.12(aromatic C-H stretching); 2927.8( aliphatic 
C-H stretching) ; 1572.66(C=N stretching) ; 1627.14(C=O stretching); 
1508.44(C=C stretching); 1311.84 (C-N stretching); 1088.62(C-O-C) ; 
1038.48(C-F stretching);765.48(mono-substituted aromatic ring) 
 
6.2.2 IR spectra of synthesised compounds 
 
 
Compound S5a 
Compound S5b 
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Compound S5c 
Compound S5d 
Compound S5e 
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Compound S5f 
Compound S5g 
Compound S5h 
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Compound S5i 
Compound S5j 
Compound S5k 
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Compound S5m 
Compound S5l 
Compound S5n 
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Compound S5o 
Compound S6a 
Compound S6b 
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Compound S6c 
Compound S6d 
Compound S6e 
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6.2.3 NMR spectra of compounds S5i and S5m 
 
Figure 6.1 NMR Spectra of compound S5i 
Compound S6f 
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Figure 6.2 NMR spectra  of compound S5m 
 
6.2.4 Mass spectra of compounds S5i and S5m 
 
Figure 6.3 Mass spectra of compound S5i 
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Figure 6.4 Mass spectra of compound S5m 
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CHAPTER 7 
RESULT AND DISCUSSION (PHARMACOLOGICAL ACTIVITY) 
7.1. In vitro antioxidant activity. 
Free radicals are key signalling molecules that play an important role in the progression of 
inflammatory disorders. An enhanced ROS generation by polymorphonuclear neutrophils at 
the site of inflammation causes endothelial dysfunction and tissue injury. These reactive 
radicals and oxidants may injure cells and  tissue directly via oxidative degradation of 
essential cellular components as well as injure cells indirectly by altering the 
protease/antiprotease balance that normally exist within the tissue interstitium. The Reactive 
oxygen metabolites may also initiate and/or amplify inflammation via the up regulation of 
several genes involved in the inflammatory response such as those code for pro inflammatory 
cytokines and adhesion molecules. Thus maintaining adequate anti-oxidant status may 
provide an useful approach in attenuating inflammation. 
Previous studies suggest that the compounds with quinolin-2-one nucleus posess remarkable 
anti-oxidant activity.Also,the anti-oxidant potential evaluation is inevitable as  quinolin-2-one 
is isosteric to coumarins, which are well known for its anti-oxidant property. The anti-oxidant 
activity of all the synthesised compounds was evaluated by using DPPH and ABTS assay. 
The IC50 values were calculated using Graphpad prism5 software and compared with that of 
ascorbic acid and quercetin.TheIC50 value is defined as the concentration of antioxidant 
required for 50% scavenging of radicals and lower IC50 value corresponds to a higher 
antioxidant activity. The antioxidant activity of the compound was measured in terms of 
hydrogen donating or radical scavenging ability, using the DPPH method. The mechanism of 
ABTS assay is based upon the electron donating radical scavenging reaction by antioxidants 
which prevent the formation of coloured ABTS radical. The IC50 values of the synthesised 
compounds were compared with that of ascorbic acid and quercetin.The in vitro anti-oxidant 
activity of synthesised compounds in ABTS and DPPH radical scavenging assay as tabulated 
in Table 7.2 and Table 7.4. The results demonstrate that the tested compounds serve as free 
radical scavenger/inhibitor, acting possibly as primary antioxidants 
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7.1.1 DPPH radical scavenging assay: 
Table 7.1 DPPH Radical scavenging activity of ascorbic acid and quercetin by DPPH 
method 
Ascorbic acid IC50 (µg/mL) Quercetin IC50 (µg/mL) 
Concentration 
 (µg/mL) 
% 
Inhibition 
 
 
 
 
 
 
10.12 
Concentration  
(µg/mL) 
%  
inhibition  
 
 
 
 
 
 
10.38 
0.5 2.74 5 20.33 
1 3.32 10 44.50 
1.5 5.08 15 66.08 
2 6.66 20 86.82 
2.5 7.60 25 96.69 
5 20.98 30 97.84 
10 50.36  
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Figure 7.1DPPH radical scavenging activity of ascorbic acid and quercetin. 
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Table 7.2DPPH radical scavenging activity of synthesised compounds 
Cpd code Percentage inhibition(%) IC50 
(µg/mL) Concentration(µg/mL) 
33.33 66.66 133.33 200 266.66 333.33 
S5a 1.37 2.02 382 5.44 6.84 7.85 >1000 
S5b 2.08 2.12 2.44 2.94 3.03 3.47 >1000 
S5c 1.37 3.17 3.82 6.92 8.30 11.80 >1000 
S5d 1.52 1.68 3.59 7.06 9.92 18.68 >1000 
S5e 1.03 1.06 1.63 2.78 5.24 8.44 >1000 
S5f 7.71 9.75 14.08 15.83 17.43 32.5 >1000 
S5g 2.53 17.67 29.30 42.43 53.56 66.85 231.3 
S5h 20.10 21.6 33.81 43.33 51.11 52.82 283.8 
S5i 29.80 54.80 78.02 88.7 91.80 93.25 58.26 
S5j 14.75 20.14 30.53 48.08 62.02 68.02 208.7 
S5k 7.26 8.88 21.4 30.65 32.31 34.11 619.8 
S5l 25.94 39.25 44.43 54.96 63.95 68.25 151.8 
S5m 28.55 36.03 52.94 62.00 65.52 67.55 118.9 
S5n 7.90 9.50 39.60 44.07 52.00 71.61 214.9 
S5o 5.69 7.62 10.67 22.64 25.21 32.11 667.4 
S6a 1.67 4.36 25.81 40.42 59.86 63.61 235.8 
S6b 7.5 11.86 21.08 32.05 54.11 63.87 258.9 
S6c 18.79 40.29 74.96 78.62 91.01 97.71 79.33 
S6d 7.89 14.01 18.83 31.11 34.41 45.04 447.2 
S6e 12.20 18.40 28.78 38.91 53.65 55.07 272.5 
S6f 21.78 31.83 51.00 67.15 77.82 83.58 112.8 
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DPPH radical scavenging activity - S5f, S5g, S5h
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Figure7.2 DPPH radical scavenging activity of synthesised compounds S5a-o; S6a-e 
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Figure7.2a DPPH radical scavenging activity of synthesised compounds S6d-f 
 
DPPH is the most extensively used assay to detect antioxidant activity.Its violet colour 
disappears in the presence of substance which can donate a hydrogen depending on the 
antioxidant activity[92]. This assay is being used as preliminary test which provides 
information on the reactivity of the test compounds with a stable free radical since odd 
electron of DPPH gives strong absorption band at 517 nm (violet colour) and when it is 
quenched by the test compound, there is a decrease in absorbance. The IC50 values for 
ascorbic acid and quercetin were found to be 10.12 µg/mL and 10.38 µg/mL  respectively  
Among the synthesised compounds compound S5i, S6c, S6f, and S5m showed more 
significant activity with IC50 values 58.26 µg/mL,79.33 µg/mL,112.8 µg/mL, and 118.9 
µg/mL respectively.  
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7.1.2 ABTS radical scavenging assay: 
Table 7.3ABTS radical scavenging activity of ascorbic acid and quercetin. 
Ascorbic acid IC50 
(µg/mL) 
Quercetin IC50 
(µg/mL) 
Concentration 
(µg/mL) 
(%) 
Inhibition 
 
 
 
 
0.93 
Concentration 
(µg/mL) 
(%) 
inhibition 
 
 
 
 
0.19 
0.2 26.79 0.25 62.50 
0.4 32.17 0.50 69.15 
0.6 34.94 0.75 79.37 
0.8 38.64 1.0 86.34 
1.0 43.49 1.25 99.47 
1.5 63.04 1.50 99.57 
2.0 80.22  
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ABTS radical scavenging assay- Quercetin
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Figure 7.3ABTS Radical scavenging activity of ascorbic acid and quercetin 
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Table 7.4  ABTS  Radical scavenging activity of synthesised compounds 
Compound 
code 
Percentage inhibition(%) IC50 
(µg/mL) Concentration(µg/mL) 
0.5 1 2.5 5 10 
S5a 28.23 38.06 39.93 56.85 57.24 4.15 
S5b 31.75 32.35 33.20 38.40 46.96 12.19 
S5c 27.63 32.95 34.04 39.84 60.61 7.14 
S5d 24.05 26.83 30.04 52.04 56.71 6.19 
S5e 20.5 20.76 24.28 32.86 51.34 13.66 
S5f 16.33 18.51 22.03 29.88 39.33 19.73 
S5g 22.01 23.29 31.73 33.60 52.93 14.08 
S5h 22.69 30.69 34.86 38.15 54.35 12.09 
S5i 10.43 10.74 19.52 26.52 46.02 14.06 
S5j 16.89 17.89 26.92 31.26 46.86 16.10 
S5k 17.10 24.60 27.00 33.64 44.15 21.13 
S5l 1961 21.84 26.20 27.54 32.81 17.78 
S5m 19.99 20.76 38.40 44.16 63.74 5.49 
S5n 25.36 28.10 33.88 33.35 47.76 14.65 
S5o 20.78 28.26 28.84 29.92 30.33 16.10 
S5a 24.97 25.54 27.81 34.05 39.49 16.18 
S5b 30.59 31.06 35.45 38.33 39.99 19.79 
S5c 21.55 22.45 24.15 27.08 38.28 13.30 
S5d 21.76 25.66 38.77 42.22 46.22 12.09 
S5e 22.64 26.44 27.98 31.20 40.50 13.13 
S5f 23.61 27.10 28.81 40.54 51.54 11.49 
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ABTS radical scavenging assay- S5d, S5e
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ABTS radical scavenging assay- S5f, S5g, S5h
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ABTS radical scavenging assay- S5j, S5j, S5k, s5l
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ABTS radical scavenging assay- S5m, S5n, S5o
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ABTS radical scavenging assay- S6a, S6b, S6c
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Figure7.4 ABTS Radical scavenging activity of synthesised compounds S5a-o; S6a-e 
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Figure7.4a ABTS Radical scavenging activity of synthesised compounds S6d-f 
 
The decolourisation of ABTS radical is an unambiguous way to measure antioxidant activity. 
In this assay, ABTS is converted to its radical cation by addition of sodium per sulphate. The 
radical cation is blue in colour and absorbs light at 734 nm. The ABTS radical reactions 
involve electron transfer and take place at a much faster rate compared to DPPH radicals.[93] 
IC50 values of standard compounds ascorbic acid and quercetin was found to be 0.93 µg/mL 
and 0.19µg/mL respectively. Compounds S5a, S5m and S5c were found to posess 
considerable antioxidant activity with IC50 values 4.15 µg/mL,5.49 µg/mL, 7.14µg/mL 
respectively. 
After docking the designed library of molecules onto the binding pocket of COX2, based 
upon the ligand interactions with the amino acid residues and SAR from previous studies as 
well as the in vitro  anti-oxidant activity,compounds S5i and  S5m were selected for in vivo 
pharmacological evaluation to assess the anti-inflammatory and analgesic potential. 
 
7.2 Acute oral toxicity study. 
Administration of test compound 5,50,300 and 2000 mg/kg per oral caused no behavioural, 
loco motor, toxic manifestations and mortality upto 14 days. Hence, it may be inferred that  
the compound was relatively non-toxic Even though there was no mortality, the animals 
showed abdominal writhing responses within one hour of test drugs administration.Further 
testing was also performed at lower doses and the animals showed relatively less writhing 
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manifestations at a dose of 1000mg/kg. Thus therefore, for the further studies, 1/16th (125 
mg/kg) and  1/32th (62.5 mg/kg) of LD50  was selected. . 
Table 7.5 Effect of test compounds on acute toxicity in rats. 
 Response Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal  Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal  Normal 
5 Pain response Normal Normal Normal Normal Normal  Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal  Normal 
9 Gripping strength Normal Normal Normal Normal Normal  Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflex Present Present Present Present Present Present 
12 Writhing Absent  Absent  Absent  Present  Absent  Absent  
13 Pupils Normal Normal Normal Normal Normal  Normal 
14 Urination Normal Normal Normal Normal Normal  Normal 
15 Salivation Normal Normal Normal Normal Normal  Normal 
16 Skin colour Normal Normal Normal Normal Normal  Normal 
17 Lacrimation Normal Normal Normal Normal Normal  Normal 
 
7.3 Screening of anti-inflammatory activity 
7.3.1 Carrageenan induced paw edema in rats 
Effects of compound and diclofenac on carrageenan induced paw edema in rats are shown in 
Table 7.6 .Oral administration of compound at doses 62.5 and 125 mg/kg significantly 
suppressed the paw edema at fourth hour after carrageenan injection in rats.Diclofenac at a 
dose of 20mg/kg significantly suppressed paw edema at 3 and 4h after carrageenan 
administration.The inhibition of carrageenan induced inflammation in rats is an established 
model to screen compounds for potential anti-inflammatory activity.  
Sub plantar injection of carrageenan into the rat paw produces plasma extravasation and the 
inflammation characterized by increased tissue water and plasma protein exudation with 
neutrophil extravasation and metabolism of arachidonic acid by both cyclooxygenase and 
lipoxygenase enzyme pathways. The development of  carrageenan induced paw edema is 
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biphasic;the first phase occurs within one hour administration of carrageenan and is attributed 
to the release of cytoplasmic enzymes, histamine and serotonin, from mast cells[94][95] .The 
second phase begins after 1h and remains through 3h which is mediated by an increased 
release of prostaglandins in the inflammatory area and continuity between the two phases is 
provided by kinins. 
Effects of compounds S5i and S5m (62.5 and 125 mg/kg)  and diclofenac (20 mg/kg) are 
shown in table 7.6 Diclofenac at a dose of 20mg/kg significantly supressed more than 50% 
paw edema from 3h. In the control group, paw edema volume was maximum at the 4h. 
Some NSAIDs strongly inhibit the second phase of carrageenan induced paw edema, but 
some others are effective against both phases.In the present study, the  compounds S5i and 
S5m at doses 62.5 and 125 mg/kg seems effective only in the second phase as the paw edema 
volume was supressed more than 50% in 4h.  So this compounds might be blocking 
prostaglandin and /or bradykinin release rather than histamine and/or serotonin. Diclofenac 
also has shown similar effect only at second phase. 
 
Table 7.6 In vivo anti-inflammatory activity of the compounds S5i and S5m by 
carrageenan induced paw edema in rats. 
Grou
ps 
Treatment Mean paw edema volume (mL) and percentage inhibition 
(%) 
1h 2h 3h 4h 5h 
I Carrageenan 
1%w/v 
(0.1mL)p.o 
0.23±0.00 0.29±0.005 0.42±0.02 0.46±0.018 0.17±0.01 
II Diclofenac 
20mg/kg 
i.p 
0.18±0.00
3* 
0.17±0.004
*** 
0.12±0.001
*** 
0.07±0.003
*** 
0.01±0.002
*** 
21.7 41.37 71.42 84.89 94.11 
III Compound 
S5i(62.5mg/kg) 
           p.o 
0.22±0.00
2 ns 
0.25±0.004
*** 
0.20±0.015
** 
0.19±0.01*
** 
0.14±0.01 
ns 
4.37 13.7 52.38 58.69 17.64 
IV Compound 
S5i(125mg/kg) 
p.o 
0.21±0.00
3 ns 
0.24±0.007
*** 
0.19±0.002
*** 
0.16±0.05*
** 
0.14±0.004 
ns 
8.69 17.24 54.70 65.21 17.64 
V Compound 
S5m(62.5mg/kg
)p.o 
0.21±0.00
6ns 
0.20±0.002
*** 
0.18±0.002
*** 
0.15±0.01*
** 
0.16±0.009
7ns 
8.69 31.03 57.14 67.39 5.86 
VI Compound 
S5m(125mg/kg)
p.o 
0.19±0.01
1* 
0.18±0.006
*** 
0.14±0.01*
** 
0.08±0.003
*** 
0.15±0.013 
ns 
17.39 39.93 66.60 82.60 11.71 
Values are mean ±SEM of 6 animals in a group.*p<0.05, of ANOVA followed by Dunnets 
test compared with control. 
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Figure 7.5 In vivo anti-inflammatory activity of the compounds S5i and S5m by carrageenan 
induced paw edema in rats 
7.3.2 Cotton pellet-induced granuloma in rats[96][97] 
Effects of compound and Diclofenac on cotton pellet-induced paw granuloma in rats are 
shown in Table 7.7 .Oral administration of compound at doses 62.5 mg/kg and125 mg/kg 
relatively inhibited the cotton pellet induced granuloma in rats. Compound S5m showed 
comparatively more significant inhibition of inflammatory response. 
Table 7.7 In vivo anti-inflammatory activity by of the compoundsS5i and S5m cotton 
pellet- induced  granuloma in rats. 
Groups Treatment and Dose Weight of dry cotton pellet 
granuloma(mg) 
(Mean±SEM) 
% Inhibition of 
granuloma formation 
I 1% w/v CMC 
p.o 
101±0.002 - 
II Diclofenac 
(20mg/kgi.p) 
43.2±0.001** 57.2 
III Compound 
S5i(62.5mg/kg)p.o 
65.1±0.002ns 35.54 
IV Compound 
S5i(125mg/kg)p.o 
55.3±0.011* 45.24 
V Compound 
S5m(62.5mg/kg)p.o 
64.2±0.001ns 36.40 
VI Compound 
S5m(125mg/kg)p.o 
51.4±0.003* 49.10 
Values are mean ±SEM of 6 animals in a group.*p<0.05, of ANOVA followed by Dunnets 
test compared with control. 
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Figure 7.6 In vivo anti-inflammatory activity by of the compounds S5i and S5m cotton 
pellet- induced  granuloma in rats. 
The anti-inflammatory activity of the compounds can be justified by the docking study of the 
ligands with COX-2 enzyme binding pocket.[98] The ligand interaction and the binding poses 
of compound S5i and S5mare given in figure 7.7 and 7.8. The ligand S5i in the COX-2 
binding pocket is stabilised within the binding site through H-bond interactions with residues 
Met 522, Val 523, Gly 526 and electronic interactions with residues His 90, Thr  94, Val 349, 
Ser 353. The ligand S5m in the COX-2 is stabilised within  the binding site through H-bond 
interactions with residues Met 522, Val 523, Ala 527, Ser 353 and electronic interactions 
with residues His90, Ser 353, Arg 513, Ala 516,  Gly 52. 
 
Figure 7.7 Binding poses  and ligand interactions of compounds S5i 
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Figure 7.8 Binding poses and ligand interactions of compounds S5m 
7.4 Screening of analgesic activity: 
7.4.1 Eddy’s hot plate [99] 
The paws of mice and rats are very sensitive to heat at temperatures which are not damaging 
the skin. The responses are jumping, withdrawal of the paws and licking of the paws. The 
time until these responses occur is prolonged after administration of centrally acting 
analgesics, whereas peripheral analgesics of the acetylsalicylic acid or phenyl-acetic acid type 
do not generally affect these responses. Both of the compounds S5i and S5m (62.5 and 125 
mg/kg) showed no significant prolongation of pain response reaction time and hence it drives 
us to the assumption that the titled compounds does not interrupt the central pain pathways. 
Table 7.8 In vivo analgesic activity of the compounds S5i and S5m by hot plate method 
in mice. 
Groups Treatment and 
Dose 
 
               Reaction time (sec) at different time intervals  
  0 min  15 min  30 min 45min   90 min 
I Morphine  
(5mg/kg i.p) 
2.33±0.210 3.33±0.21*** 6.01±0.365*** 9.33±0.55*** 11.00±0.36*** 
II Compound S5i 
(62.5mg/kg)p.o 
1.67±0.33 3.0±0.001ns 3.33±0.88ns 3.33±0.66ns 4.23±0.33* 
III Compound S5i 
(125mg/kg)p.o 
2.33±0.33 3.02±0.001ns 4.2±0.015** 4.66±0.33*** 4.3±0.33*** 
IV Compound 
S5m 
(62.5mg/kg)p.o 
2.01±0.02 3.02±0.51ns 3.12±0.21ns 3.66±0.33* 4.0±0.57* 
V Compound 
S5m 
(125mg/kg)p.o 
2.33±0.33 3.00±0.57ns 4.13±0.012ns 4.66±0.33* 4.66±0.667* 
Values are mean ±SEM of 6 animals in a group.*p<0.05 compared with reaction time before 
drug treatment. Data were analyzed by using One-way ANOVA followed by Dunnett’s test 
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Figure 7.9 In vivo analgesic activity of the compounds S5i and S5m by hot plate method 
in mice. 
 
7.4.2 Acetic acid induced writhing test in mice 
Acetic acid induced writhing test is a model of visceral or peritoneal pain in animals. Intra 
peritoneal administration of acetic acid irritates serous membranes and provoke a stereotyped 
behaviour known as writhing which involves turning movements of the body and extension 
of hind limbs. These behaviours are considered as reflexive and are evidence of peritoneo-
visceral or visceral pain associated with visceral chemoreceptors.  
The effect of compounds S5i and S5m (62.5 and 125 mg/kg,p.o) and Diclofenac sodium 
(20mg/kg i.p)  were evaluated by acetic acid induced writhing responses in mice. The number 
of writhings of each animal within 15 min after acetic acid injection was cumulatively 
counted immediately and the percentage protection was calculated using the following ratio.    
Percentage of protection = (Control mean – treated mean) / (control mean) x 100 
The effects of compound and Diclofenac on writhing test are shown in Table 7.9. The 
compound at respective doses  significantly inhibited the writhing response of mice caused 
by intraperitoneal injection of acetic acid. Since the abdominal constriction induced by acetic 
acid involves the process of release of arachidonic acid metabolites via cyclooxygenase 
(COX) and prostaglandin biosynthesis.So the compound may act by inhibiting the release of 
arachidonic acid which adds on evidence deriving the conclusion that the titled compounds 
act by blocking the COX pathway.  
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Table 7.9 In vivo analgesic activity of the compounds S5i and S5m by acetic acid 
Induced writhing in mice. 
Groups Treatment and Dose Number of writhing 
(Mean±SEM) 
Percentage 
protection(%) 
I 1% w/v CMC 56.25±1.109  
II Diclofenac(20mg/kg) 
i.p 
32.00±0.912*** 43.11 
III Compound 
S5i(62.5mg/kg)p.o 
46.00±2.160** 18.22 
IV Compound 
S5i(125mg/kg)p.o 
35.00±2.09*** 37.77 
V Compound 
S5m(62.5mg/kg)p.o 
42.50±1.708*** 24.44 
VI Compound 
S5m(125mg/kg)p.o 
33.50±1.080*** 40.17 
Values are mean ±SEM of 6 animals in a group.*p<0.05 compared with the control. Data 
were analyzed by using One-way ANOVA followed by Dunnett’s test 
 
 
. 
 
Figure 7.10 In vivo analgesic activity of the compounds S5i and S5m by acetic acid 
Induced writhing method in mice 
 
7.5 Ulcerogenic effect[100] 
NSAIDs are often accompanied by side effects in which the gastric irritation is more common 
and prominent. The gastric mucosa protects itself from gastric acid with a layer of mucus,the 
secretion of which is stimulated by certain prostaglandins. The non selective inhibition of 
COX enzymes are primary cause for gastric irritation as it blocks COX1 which is essential 
for the prostaglandin synthesis 
The ulcerogenic potential of the titled compounds were studied after observation of stomach 
of fasted rats after 5h of administration of compounds and compared with indomethacin(10 
mg/kg p.o).  The presence of mucosal erosion, ulcers and perforations were investigated. No 
signs of ulceration were observed after 5h of drug administration of the compounds S5i and 
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S5m  at the doses which it displayed anti-inflammatory and analgesic activity (62.5 and 
125mg/kg) thus indicating the safety of the drug. On the other hand  indomethacin (10 
mg/kg) showed 3 spot ulcers under microscopical evaluation (10X). This lead us the 
assumptions that the titled compounds might be selective inhibitors of COX-2.Further 
enzyme inhibition assays are essential to confirm the selectivity of the compounds. 
 
 
 
Figure 7.11 Ulcerogenic potential studies. A. Normal; B. Indomethacin (10mg/kg.p.o); 
C. Compound S5i (62.5 mg/kg) p.o; D. Compound S5i (125 mg/kg) p.o; E. Compound S5m 
(62.5 mg/kg) p.o; F. Compound S5m (125 mg/kg) p.o. 
 
7.6 ANTI BACTERIAL STUDIES 
The structure activity relationships of compounds based on nalidixic acid have led to a large 
group of synthetic antibacterial agents known collectively as quinolones. The 4-quinolones 
such as ciprofloxacin, ofloxacin, lomefloxacin, enoxacin are established synthetic 
antibacterial agents as DNA gyrase inhibitors . The benzopyrone ring in compounds of 
coumarinsand flavones is isosteric to quinolones and has shown DNA gyrase inhibition. The 
quinolin-2-ones, also called carbostyrils or 1-aza coumarins, are isosteric to coumarins and 
isomeric to 4-quinolones and could become a potential candidate for antibacterial activity.[101] 
All the compounds were screened for antibacterial activity against various strains of 
pathogenic bacteria by using disc diffusion method. The compounds (S6f and S5j) which 
showed considerably higher percentage zone of inhibition were selected for determination of 
Minimum inhibitory concentration(MIC). The zone of inhibition and percentage growth of 
inhibition of all the synthesised compounds against various strains of bacteria are shown in 
Table 7.10 
Based upon the zone of inhibition two compounds were selected for determining 
MIC. Minimum inhibitory concentration is the lowest concentration that prevents visible 
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growth of an organism. Compound S5j and S6f were found to have considerable anti 
bacterial activity with MIC of 25µg/mL against Pseudomonas aeuroginosa and 50µg/mL 
against Bacillus subtilis. 
 
Table 7.10 Antibacteralstudies : zone of inhibition and percentage growth of inhibition 
Cpd 
code 
Zone of inhibition(mm) and percentage growth inhibition(%) 
E.coli k.Pneumoniae S.Paratyphi V.cholorae P.aeuroginosa S.aureus B.subtilis 
S5a - - - - - - - 
S5b - - - - - - - 
S5c - - - - - - - 
S5d - - - - - - - 
S5e 7(41.1) 9(23.04) - - - - - 
S5f - 11(28.2) - - - - - 
S5g - 7(17.90) - - - - - 
S5h -  - - - - - 
S5i - 10(25.6) - - - - - 
S5j - - - - 21(70.0) 11(45.83) - 
S5k - - - - - 7(29.16) - 
S5l - - - - - - - 
S5m - - - - 10(33.33) 10(41.66) - 
S5n 7(41.1) 10(25.6) - - - - 9(64.28) 
S5o 9(52.9)  - - 12(40) - - 
S6a - 11(28.2) - 15(45.54) - - - 
S6b - 11(28.2) - 19(57.57) - - - 
S6c - 10(25.6) - - - - - 
S6d - 10(25.6) - - - - - 
S6e -  - 20(60.60) 10(33.33) - 5(35.71) 
S6f - 12(30.76) - - 13(43.33) - 13(92.85) 
Cpf 17 39 18 33 30 24 14 
- : No inhibition; Cpf: Ciprofloxacin 
  
Figure 7.12 MIC of compounds S5j; S6f 
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